Silvio Danese

Silvio Danese's AcademicInfluence.com Rankings

Silvio Danese

Philosophy

#2931

World Rank

#4857

Historical Rank

Logic

#859

World Rank

#1416

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Silvio Danese's Degrees

Doctorate Medicine University of Milan
PhD Gastroenterology University of Milan

Why Is Silvio Danese Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Silvio Danese's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) (1847)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. (2010) (1578)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target (2015) (1329)
Epithelial NEMO links innate immunity to chronic intestinal inflammation (2007) (1051)
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. (2014) (780)
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial (2016) (666)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017) (611)
The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) (600)
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. (2013) (567)
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease (2011) (557)
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial (2017) (549)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. (2020) (529)
Tolerogenic dendritic cells: cytokine modulation comes of age. (2006) (513)
Development of the Crohn's disease digestive damage score, the Lémann score (2010) (511)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. (2017) (505)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. (2013) (477)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2019) (472)
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management (2020) (440)
European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. (2015) (422)
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study (2010) (408)
Inflammatory bowel disease: the role of environmental factors. (2004) (398)
Regulation of leukocyte recruitment by the long pentraxin PTX3 (2010) (396)
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. (2006) (368)
Ulcerative colitis. (2011) (350)
Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens (2007) (345)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. (2019) (329)
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. (2011) (314)
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. (2011) (308)
New therapies for inflammatory bowel disease: from the bench to the bedside (2011) (298)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. (2010) (294)
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. (2009) (285)
Development and validation of the Nancy histological index for UC (2015) (285)
Etiopathogenesis of inflammatory bowel diseases. (2006) (285)
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. (2016) (280)
Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation1 (2007) (279)
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study (2020) (279)
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. (2016) (276)
Intestinal microbiota in inflammatory bowel disease: friend of foe? (2011) (276)
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. (2017) (257)
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients (2003) (254)
Biologic agents for IBD: practical insights (2015) (252)
Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses. (2019) (251)
High density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis (2014) (250)
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. (2015) (247)
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study (2013) (242)
Application of Artificial Intelligence to Gastroenterology and Hepatology. (2019) (240)
Platelets in Inflammatory Bowel Disease: Clinical, Pathogenic, and Therapeutic Implications (2004) (238)
Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project (2012) (235)
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. (2008) (222)
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. (2006) (216)
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. (2016) (212)
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease (2011) (210)
Extraintestinal manifestations in inflammatory bowel disease. (2005) (205)
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. (2003) (205)
ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). (2013) (196)
Biological Agents for Moderately to Severely Active Ulcerative Colitis (2014) (194)
Ulcerative colitis (2020) (194)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. (2017) (191)
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer (2010) (187)
Cutting Edge: T Cells Trigger CD40-Dependent Platelet Activation and Granular RANTES Release: A Novel Pathway for Immune Response Amplification1 (2004) (185)
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study (2015) (183)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. (2017) (182)
Crohn’s disease (2020) (179)
Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine. (2015) (178)
MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. (2012) (176)
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. (2014) (170)
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes (2018) (169)
Long-term Efficacy of Vedolizumab for Ulcerative Colitis (2016) (168)
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. (2012) (165)
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
Long-term Efficacy of Vedolizumab for Crohn’s Disease (2016) (164)
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists (2017) (162)
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study* (2011) (159)
Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance1 (2005) (156)
The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6 (2009) (156)
Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease (2016) (152)
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. (2013) (149)
The CD40/CD40L costimulatory pathway in inflammatory bowel disease (2004) (148)
The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. (2010) (143)
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis. (2020) (141)
Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy (2020) (140)
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes (2018) (139)
TNF-α Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn’s Disease1 (2006) (137)
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. (2014) (135)
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. (2015) (135)
Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial (2011) (133)
Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. (2008) (133)
Comparing histological activity indexes in UC (2014) (132)
Endoscopic Mucosal Resection for Early Colorectal Neoplasia: Pathologic Basis, Procedures, and Outcomes (2009) (127)
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial (2017) (126)
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials (2015) (126)
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study (2014) (125)
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar (2017) (124)
Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double‐blind, randomised, placebo‐controlled study (2013) (123)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (2020) (122)
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. (2016) (121)
Homocysteine Triggers Mucosal Microvascular Activation in Inflammatory Bowel Disease (2005) (121)
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. (2007) (120)
Identification of serum and tissue micro‐RNA expression profiles in different stages of inflammatory bowel disease (2013) (119)
Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease (2017) (119)
Ulcerative colitis. (2020) (119)
Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti‐TNF‐α therapy (2011) (119)
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. (2009) (117)
Angiogenesis blockade as a new therapeutic approach to experimental colitis (2006) (115)
Management of IBD during the COVID-19 outbreak: resetting clinical priorities (2020) (114)
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). (2014) (113)
Systematic review with network meta‐analysis: comparative assessment of tofacitinib and biological therapies for moderate‐to‐severe ulcerative colitis (2018) (113)
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme (2019) (113)
Review Article: Inherited Thrombophilia in Inflammatory Bowel Disease (2003) (112)
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. (2005) (111)
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis (2019) (111)
Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications (2017) (110)
Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. (2019) (109)
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts (2020) (107)
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. (2016) (107)
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. (2014) (105)
Galectin-4 Controls Intestinal Inflammation by Selective Regulation of Peripheral and Mucosal T Cell Apoptosis and Cell Cycle (2008) (104)
Next generation of small molecules in inflammatory bowel disease (2016) (103)
Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. (2005) (103)
Review article: anti TNF‐α induced psoriasis in patients with inflammatory bowel disease (2009) (102)
WallFlex colonic stent placement for management of malignant colonic obstruction: a prospective study at two centers. (2008) (100)
Assessment and Grading of Mucosal Inflammation in Colonic Diverticular Disease (2008) (99)
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta‐analysis (2019) (98)
Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn’s disease and ulcerative colitis (2004) (98)
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. (2021) (98)
High Prevalence of Celiac Disease in Patients with Lactose Intolerance (2005) (97)
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. (2017) (96)
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II) (2017) (96)
Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. (2018) (95)
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. (2015) (95)
Chemokines in inflammatory bowel disease (2005) (95)
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon (2015) (95)
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice (2008) (95)
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. (2006) (94)
Clinical experience with a new endoscopic over-the-scope clip system for use in the GI tract. (2009) (93)
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. (2016) (93)
Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience (2011) (92)
Development of an index to define overall disease severity in IBD (2016) (92)
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process (2012) (92)
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms (2021) (92)
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease (2001) (91)
Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations (2017) (90)
Increased carotid intima–media thickness in patients with inflammatory bowel disease (2005) (89)
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. (2020) (87)
Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future (2013) (87)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial (2021) (87)
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. (2004) (85)
Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. (2014) (85)
Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection. (2016) (84)
Adalimumab in active ulcerative colitis: a "real-life" observational study. (2012) (84)
Big data in IBD: a look into the future (2019) (83)
Colitis-associated cancer: the dark side of inflammatory bowel disease (2011) (81)
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. (2014) (80)
Biosimilars in IBD: from theory to practice (2017) (80)
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? (2019) (79)
Critical role of the CD40–CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease (2007) (78)
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. (2010) (77)
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period (2020) (77)
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience (2020) (77)
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease (2016) (75)
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis (2020) (75)
Novel therapeutic targets for inflammatory bowel disease. (2017) (74)
Early intervention in Crohn’s disease: towards disease modification trials (2017) (74)
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. (2014) (74)
Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce (2020) (74)
Systematic review with meta‐analysis: use of 5‐aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease (2017) (72)
Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study (2012) (72)
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission (2013) (71)
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? (2018) (70)
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. (2020) (69)
Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. (2007) (68)
Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies (2015) (68)
Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2 (2018) (67)
JAK inhibition in inflammatory bowel disease (2017) (67)
Risk factors for complications after ileocolonic resection for Crohn’s disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study (2016) (66)
Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation (2011) (65)
Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. (2015) (65)
Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis (2014) (64)
New therapeutic avenues in ulcerative colitis: thinking out of the box (2013) (64)
Review article: the histological assessment of disease activity in ulcerative colitis (2015) (64)
Early atherosclerosis in patients with inflammatory bowel disease. (2006) (64)
Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. (2013) (63)
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis (2014) (63)
Assessment of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Plasma Levels in Inflammatory Bowel Diseases (2004) (63)
Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. (2008) (63)
The nocebo effect: a clinical challenge in the era of biosimilars (2018) (63)
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study (2018) (62)
Second-Generation Corticosteroids for the Treatment of Crohn’s Disease and Ulcerative Colitis: More Effective and Less Side Effects? (2012) (62)
Guideline / Consensus Paper 3 rd European Evidence-based Consensus on the Diagnosis and Management of Crohn ’ s Disease 2016 : Part 2 : Surgical Management and Special Situations (2017) (62)
Endoscopic flexible treatment of Zenker's diverticulum: a modification of the needle-knife technique. (2010) (61)
Comorbidities in inflammatory bowel disease: a call for action. (2019) (61)
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn’s Disease and Guiding Clinical Decision-making (2018) (60)
ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology. (2020) (60)
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey (2020) (59)
Evolving therapeutic goals in ulcerative colitis: towards disease clearance (2019) (59)
Review article: optimal preparation for surgery in Crohn's disease (2014) (59)
Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: ‘brothers in arms’ (2011) (59)
Integrated models of care in managing inflammatory bowel disease: a discussion. (2012) (59)
Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. (2013) (58)
Results from the 2 nd Scientific Workshop of the ECCO ( I ) : Impact of mucosal healing on the course of inflammatory bowel disease (2011) (58)
NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high anti-tumor activity against colorectal cancer. (2019) (58)
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? (2013) (57)
Vascular Involvement in Inflammatory Bowel Disease: Pathogenesis and Clinical Aspects (2008) (57)
Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease (2000) (57)
Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease (2015) (56)
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa. (2001) (56)
Long‐term safety of vedolizumab for inflammatory bowel disease (2020) (55)
Surgical rates in the era of biological therapy: up, down or unchanged? (2017) (55)
The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease (2009) (55)
Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn’s and Ulcerative Colitis Association’s online survey (2014) (54)
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn’s Disease and its Impact on Disease Outcome (2016) (54)
Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries (2013) (53)
Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease (2018) (53)
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open (2019) (53)
Short-Term Outcomes of Laparoscopy Combined with Enhanced Recovery Pathway after Ileocecal Resection for Crohn’s Disease: a Case-Matched Analysis (2012) (51)
Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. (2011) (51)
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. (2018) (51)
Ulcerative Colitis and Crohn's Disease Have the Same Burden and Goals for Treatment. (2019) (51)
Colonic diverticular disease (2020) (51)
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. (2012) (50)
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (2020) (50)
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus (2019) (50)
Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's Disease (2011) (50)
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy (2020) (50)
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. (2013) (50)
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis (2021) (50)
Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor (2020) (49)
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. (2018) (49)
Role of Helicobacter pylori CagA + Infection in Determining Oxidative DNA Damage in Gastric Mucosa (2002) (49)
Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. (2000) (49)
Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow (2007) (49)
Familial aggregation in inflammatory bowel disease: is it genes or environment? (2011) (49)
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. (2010) (48)
Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases (2017) (48)
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience (2019) (48)
Nonimmune cells in inflammatory bowel disease: from victim to villain. (2008) (48)
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. (2018) (48)
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials (2018) (48)
Review article: integrating budesonide‐MMX into treatment algorithms for mild‐to‐moderate ulcerative colitis (2014) (47)
New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets. (2008) (47)
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis (2017) (47)
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic (2020) (45)
Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease (2018) (45)
Colorectal cancer prevention in patients with ulcerative colitis. (2018) (45)
Review article: faecal calprotectin and histologic remission in ulcerative colitis (2020) (45)
Catching the therapeutic window of opportunity in early Crohn's disease. (2014) (45)
Perception of Reproductive Health in Women with Inflammatory Bowel Disease. (2016) (45)
The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity. (2007) (45)
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue (2017) (45)
The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti‐integrin therapies (2019) (44)
Acute small-bowel perforation secondary to capsule endoscopy. (2008) (44)
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences (2019) (44)
Internet use among inflammatory bowel disease patients: an Italian multicenter survey (2009) (43)
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. (2010) (43)
Liver tests abnormalities in COVID-19: trick or treat? (2020) (43)
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease (2010) (43)
Activation of the VEGFC/VEGFR3 pathway induces tumor immune escape in colorectal cancer. (2019) (43)
Positioning therapies in ulcerative colitis. (2020) (42)
Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. (2008) (42)
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC. (2019) (42)
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies (2020) (42)
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. (2016) (42)
Proteomic Analysis of the Inflamed Intestinal Mucosa Reveals Distinctive Immune Response Profiles in Crohn’s Disease and Ulcerative Colitis1 (2007) (41)
Biological therapies for inflammatory bowel disease: research drives clinics. (2006) (41)
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). (2017) (41)
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease (2013) (41)
TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice (2018) (41)
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. (2017) (41)
Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds (2010) (40)
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock (2020) (40)
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials (2022) (40)
New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. (2010) (40)
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis (2020) (40)
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial (2015) (40)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (2022) (39)
FOXP3+ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents (2013) (39)
Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience (2020) (39)
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. (2016) (39)
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. (2019) (39)
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar‐treated IBD patients (2019) (39)
Innate immunity in Crohn's disease: the reverse side of the medal. (2008) (39)
Gastrointestinal involvement attenuates COVID-19 severity and mortality (2020) (39)
Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases. (2019) (38)
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. (2014) (38)
Comparison Between 1.5 and 3.0 Tesla Magnetic Resonance Enterography for the Assessment of Disease Activity and Complications in Ileo-Colonic Crohn’s Disease (2013) (38)
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. (2020) (38)
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study (2016) (38)
Redox Equilibrium in Mucosal T Cells Tunes the Intestinal TCR Signaling Threshold1 (2005) (38)
943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial (2012) (38)
The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis (2014) (37)
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (2021) (37)
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. (2017) (37)
The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients (2020) (37)
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease (2017) (37)
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? (2010) (36)
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment (2021) (36)
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. (2019) (36)
Microscopic features of colorectal neoplasia in inflammatory bowel diseases. (2014) (36)
Risk of postoperative recurrence and postoperative management of Crohn's disease. (2011) (36)
Review article: anti‐fibrotic agents for the treatment of Crohn’s disease – lessons learnt from other diseases (2009) (36)
MRI in Crohn's disease—current and future clinical applications (2012) (36)
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". (2017) (36)
Treatment of Perianal Fistulas in Crohn’s Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial (2019) (35)
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies (2019) (35)
Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. (2016) (35)
SARS-CoV-2 vaccination in IBD: more pros than cons (2021) (35)
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. (2016) (35)
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme (2014) (34)
Laparoscopic Surgery for Recurrent Crohn's Disease (2012) (34)
Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. (2019) (33)
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes (2015) (33)
Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. (2022) (33)
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. (2019) (33)
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial (2022) (33)
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn’s disease (2020) (33)
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA (2016) (33)
Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. (2020) (33)
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents (2017) (32)
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). (2019) (32)
Mesenteric Vascular Thromboembolism in Inflammatory Bowel Disease: A Single Center Experience (2010) (32)
Management of gastrointestinal and liver diseases during pregnancy (2014) (32)
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. (2018) (32)
Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. (2019) (32)
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience (2017) (32)
Systematic review with meta‐analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease (2020) (31)
Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis (2015) (31)
Inflammatory bowel disease: estimates from the global burden of disease 2017 study (2020) (31)
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation (2014) (31)
Preoperative Magnetic Resonance Enterography in Predicting Findings and Optimizing Surgical Approach in Crohn's Disease (2013) (30)
Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers. (2012) (30)
Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy (2020) (30)
Platelets: new players in the mucosal scenario of inflammatory bowel disease. (2004) (30)
Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. (2018) (29)
OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study (2021) (29)
Haematopoietic prolyl hydroxylase‐1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis (2017) (29)
Revisiting fibrosis in inflammatory bowel disease: the gut thickens (2021) (29)
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study (2015) (29)
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? (2014) (29)
OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study (2018) (29)
High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. (2000) (29)
Helicobacter pylori Infection Affects Eosinophilic Cationic Protein in the Gastric Juice of Patients with Idiopathic Chronic Urticaria (2001) (29)
Comparative safety of systemic and low‐bioavailability steroids in inflammatory bowel disease: Systematic review and network meta‐analysis (2018) (29)
Drug development in IBD: from novel target identification to early clinical trials (2016) (29)
Prevention and Treatment of Venous Thromboembolism in Patients with IBD: A Trail Still Climbing (2015) (29)
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy (2020) (29)
Head-to-head trials in inflammatory bowel disease: past, present and future (2020) (28)
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. (2016) (28)
The Role of JAM‐A in Inflammatory Bowel Disease: Unrevealing the Ties That Bind (2009) (28)
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. (2017) (28)
The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches (2019) (28)
Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study (2020) (28)
The biosimilar road in inflammatory bowel disease: the right way? (2014) (28)
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease (2018) (28)
The safety of biological pharmacotherapy for the treatment of ulcerative colitis (2017) (28)
Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. (2019) (28)
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial (2021) (28)
Effect of Tumor Necrosis Factor-&agr; Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease (2013) (28)
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease. (2004) (28)
Biological agents for ulcerative colitis: Hypes and hopes (2008) (28)
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial (2022) (28)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. (2022) (27)
Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
Use of Cross-sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. (2019) (27)
OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis (2019) (27)
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1 (2018) (27)
Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience. (2011) (27)
Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization (2020) (27)
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease (2013) (27)
Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? (2010) (26)
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. (2020) (26)
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy (2020) (26)
Probiotic Sonicates Selectively Induce Mucosal Immune Cells Apoptosis through Ceramide Generation via Neutral Sphingomyelinase (2011) (26)
High rate of helicobacter pylori re-infection in patients affected by type 1 diabetes. (2002) (26)
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. (2014) (26)
Preventing disability in inflammatory bowel disease (2017) (26)
Can IL-23 be a good target for ulcerative colitis? (2018) (26)
Review article: treating‐to‐target for inflammatory bowel disease‐associated anaemia (2018) (26)
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study (2018) (26)
The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13 (2015) (26)
Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm (2017) (25)
Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. (2013) (25)
Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (25)
Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management (2020) (25)
Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? (2013) (25)
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men (2018) (25)
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis (2020) (24)
The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases (2021) (24)
Integrins and adhesion molecules as targets to treat inflammatory bowel disease. (2015) (24)
Folate in gastrointestinal health and disease. (2012) (24)
Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease (2018) (24)
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study (2021) (24)
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis (2020) (24)
The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method (2013) (24)
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses (2019) (23)
Su2080 Efficacy of Budesonide MMx(r) 6 mg QD for the Maintenance of Remission in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study (2012) (23)
Patient and physician views on the quality of care in inflammatory bowel disease: results from SOLUTION-1, a prospective IG-IBD study. (2014) (23)
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study (2020) (23)
Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. (2021) (23)
The role of multimodal treatment in Crohn′s disease patients with perianal fistula: a multicentre retrospective cohort study (2018) (23)
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease (2021) (23)
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn’s Disease (2018) (23)
Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation (2020) (23)
767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials (2016) (22)
Proximal collagenous gastroenteritides: Clinical management. A systematic review (2014) (22)
E-health in inflammatory bowel diseases: More challenges than opportunities? (2017) (22)
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients (2012) (22)
Unmet Needs in IBD: the Case of Fatigue (2018) (22)
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. (2019) (22)
Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology? (2013) (22)
Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition (2018) (22)
Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow-up survey (2019) (22)
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience (2020) (22)
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. (2021) (22)
VEGF in inflammatory bowel disease: a master regulator of mucosal immune-driven angiogenesis. (2008) (22)
Preventing Collateral Damage in Crohn's Disease: The Lémann Index. (2016) (22)
TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. (2020) (21)
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. (2019) (21)
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. (2008) (21)
Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI (2019) (21)
Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late. (2008) (21)
Ustekinumab in the management of Crohn's disease: Expert opinion. (2018) (21)
Disease-related and drug-induced skin manifestations in inflammatory bowel disease (2017) (21)
Point-of-care ultrasound in Inflammatory Bowel Disease. (2020) (21)
Vedolizumab for the treatment of Crohn’s disease (2018) (21)
The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework (2021) (21)
Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe (2018) (21)
Author Correction: Crohn’s disease (2020) (20)
Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522 (2012) (20)
Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. (2018) (20)
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise (2021) (20)
CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. (2004) (20)
Biosimilars of adalimumab: the upcoming challenge in IBD (2019) (20)
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. (2019) (20)
Early Intervention in Ulcerative Colitis: Ready for Prime Time? (2020) (20)
Severe liver injury associated with zafirlukast. (2001) (19)
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. (2019) (19)
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach (2018) (19)
Improving the quality of surveillance colonoscopy in inflammatory bowel disease. (2019) (19)
Management of patients with inflammatory bowel disease and spondyloarthritis (2017) (19)
Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience. (2011) (18)
Modulation of sphingosine-1-phosphate in ulcerative colitis (2020) (18)
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. (2019) (18)
Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. (2004) (18)
The day after COVID-19 in IBD: how to go back to ‘normal’ (2020) (18)
Treatments for Crohn's Disease–Associated Bowel Damage: A Systematic Review (2019) (18)
PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system (2022) (18)
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis (2021) (18)
Adalimumab in ulcerative colitis: hypes and hopes (2011) (18)
The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation. (2008) (18)
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. (2018) (18)
New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? (2009) (18)
W1223 Genetic Factors Conferring an Increased Susceptibility to Develop Crohn's Disease Also Influence Disease Phenotype, but Do Not Predict it. Results From the IBDChip European Project (2010) (17)
Positioning Ustekinumab in Crohn’s Disease: From Clinical Evidence to Clinical Practice (2017) (17)
The impact of biologics in surgical outcomes in ulcerative colitis. (2018) (17)
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease (2022) (17)
745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial (2015) (17)
JAK inhibitors: Novel developments in management of ulcerative colitis. (2018) (17)
Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases. (2006) (17)
Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases (2010) (17)
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment (2015) (17)
Prevalence of and risk factors for Helicobacter pylori infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study (2001) (17)
Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies (2010) (17)
Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. (2021) (17)
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review (2014) (16)
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication. (2001) (16)
Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? (2003) (16)
TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease (2011) (16)
OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM (2019) (16)
A practical guide for faecal calprotectin measurement: myths and realities. (2020) (16)
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II (2021) (16)
Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease (2021) (16)
775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study (2021) (16)
Diffusion-weighted MRI in inflammatory bowel disease. (2018) (16)
OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study (2020) (16)
Systematic review on IBD patients with COVID-19: it is time to take stock. (2020) (16)
Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature (2010) (15)
Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement (2020) (15)
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system (2008) (15)
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes (2016) (15)
Endothelial Cell-Immune Cell Interaction in IBD (2016) (15)
Sa1261 Vedolizumab for the Treatment of Fistulizing Crohn's Disease: An Exploratory Analysis of Data From GEMINI 2 (2015) (15)
Biosimilars – terms of use (2015) (15)
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. (2001) (15)
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. (2022) (15)
The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. (2017) (15)
Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer (2020) (15)
Fecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. (2019) (14)
Tu1252 Effect of Budesonide MMx 6 mg on the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study (2012) (14)
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy (2017) (14)
Are Surgical Rates Decreasing in the Biological Era In IBD? (2019) (14)
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease (2020) (14)
Diagnostic Delay in Crohn’s Disease: Time for Red Flags (2016) (14)
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2022) (14)
Metal stents for malignant colorectal obstruction (2006) (14)
Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic (2020) (14)
Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials (2020) (14)
Histological healing: should it be considered as a new outcome for ulcerative colitis? (2019) (14)
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces]. (2021) (14)
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. (2004) (14)
Predictive value of bowel ultrasound in Crohn's disease: a 12-month prospective study. (2021) (14)
What's hot in inflammatory bowel disease in 2011? (2011) (14)
New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? (2020) (14)
Adherence to infliximab therapy in inflammatory bowel disease patients in a real‐life setting (2017) (14)
Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11 (2019) (14)
OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study (2021) (14)
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD (2020) (14)
A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn's disease (2016) (13)
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block (2020) (13)
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting (2017) (13)
Involvement of CD40–CD40 Ligand in Uncomplicated and Refractory Celiac Disease (2011) (13)
Thiopurines’ Metabolites and Drug Toxicity: A Meta-Analysis (2020) (13)
Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results. (2022) (13)
Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis (2021) (13)
9 Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial (2013) (13)
Biological therapy for ulcerative colitis: what is after anti-TNF. (2011) (13)
Colitis, microbiota, and colon cancer: an infernal triangle. (2013) (13)
Targeting lymphatics in inflammatory bowel disease (2015) (13)
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases (2021) (13)
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. (2022) (13)
OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study (2021) (13)
OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study (2019) (12)
Cytapheresis in Inflammatory Bowel Diseases: Current Evidence and Perspectives (2008) (12)
Adalimumab in ulcerative colitis: ready for prime time. (2013) (12)
Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization (2016) (12)
Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. (2020) (12)
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters (2021) (12)
Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study (2017) (12)
Treat to target or ‘treat to clear’ in inflammatory bowel diseases: one step further? (2020) (12)
Preventing diverticulitis recurrence by selecting the right therapy for a complex disease. (2014) (12)
Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. (2020) (12)
OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. (2017) (12)
OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD) (2018) (12)
The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review (2021) (12)
Successful treatment of fistulizing Crohn's disease with certolizumab pegol. (2008) (11)
A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. (2021) (11)
Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients. (2020) (11)
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. (2021) (11)
Imaging modalities for perianal Crohn's disease. (2012) (11)
Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. (2015) (11)
Breaking through the therapeutic ceiling: what will it take? (2021) (11)
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease (2015) (11)
Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study (2021) (11)
DOP48 Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study (2019) (11)
Filgotinib in Crohn's Disease: JAK Is Back. (2017) (11)
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan (2020) (11)
Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. (2015) (11)
416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis (2019) (11)
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. (2019) (11)
DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open (2018) (11)
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis (2022) (11)
Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. (2014) (11)
Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger? (2020) (11)
Etiopathogenesis of infl ammatory bowel diseases (2006) (11)
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation (2013) (11)
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study (2020) (10)
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? (2018) (10)
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. (2020) (10)
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus (2019) (10)
Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease? (2019) (10)
Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFI (2019) (10)
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. (2019) (10)
Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs (2019) (10)
IBD: Mucosal healing—EXTENDing our knowledge in Crohn's disease (2012) (10)
Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis (2021) (10)
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. (2019) (10)
Environmental, Nutritional and Socio-Economic Determinants of IBD Incidence: A Global Ecological Study. (2020) (10)
749 Infliximab for Prevention of Recurrence of Post-Surgical Crohn's Disease Following Ileocolonic Resection: A Randomized, Placebo-Controlled Study (2015) (10)
mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn’s Disease (2019) (10)
Stopping infliximab in Crohn’s disease: still an ongoing STORI. (2012) (10)
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis (2019) (10)
Crohn's disease: bacterial clearance in Crohn's disease pathogenesis. (2010) (10)
Negative Regulators of Angiogenesis in Inflammatory Bowel Disease: Thrombospondin in the Spotlight (2008) (10)
Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance. (2007) (10)
Colifagina, a Novel Preparation of 8 Lysed Bacteria Ameliorates Experimental Colitis (2008) (9)
Long-term safety of approved biologics for ulcerative colitis (2020) (9)
Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial (2018) (9)
Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13 (2020) (9)
Cross-Sectional Imaging Modalities in Crohn's Disease (2013) (9)
Anti-TNF and postoperative complications in abdominal Crohn's disease surgery. (2019) (9)
Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. (2008) (9)
Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next? (2020) (9)
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? (2019) (9)
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target (2014) (9)
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease (2020) (9)
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy (2022) (9)
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for Inflammatory bowel disease treatment (2009) (9)
439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars (2016) (9)
In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution. (2015) (9)
Author Correction: Management of IBD during the COVID-19 outbreak: resetting clinical priorities (2020) (9)
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study (2016) (9)
The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn’s disease (2020) (9)
Mo1906 - The Effects of Vagus Nerve Stimulation in Biologicrefractory Crohn's Disease: A Prospective Clinical Trial (2018) (9)
Thrombosis in IBD in the era of JAK inhibition. (2020) (9)
Critical Evaluation of Current Concepts and Moving to New Horizons in the Management of IBD: Falk Symposium 196, Frankfurt, March 2015 (2015) (9)
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. (2022) (9)
Intestinal ischemic manifestations of SARS-CoV-2: Results from the ABDOCOVID multicentre study (2021) (9)
IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs (2013) (9)
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis (2020) (9)
Ulcerative colitis: a cinderella story. (2011) (8)
The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies (2020) (8)
Budesonide-MMx® 9 mg for Induction of Remission of Mild-to-Moderate Ulcerative Colitis (UC): Data From a Multicenter, Randomized, Double-Blind Placebo-Controlled Study in the Europe, Russia, Israel and Australia (2011) (8)
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis (2021) (8)
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn’s disease (2021) (8)
IBD: To switch or not to switch: that is the biosimilar question (2017) (8)
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. (2019) (8)
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study (2017) (8)
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron‐containing medicines (2014) (8)
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery (2020) (8)
Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme (2020) (8)
Clinical development of biologicals and biosimilars - safety concerns (2017) (8)
Targeting the gut layers in Crohn’s disease: mucosal or transmural healing? (2020) (8)
Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review (2020) (8)
Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohnʼs Disease: 669 (2017) (8)
Indirect Treatment Comparison of Ustekinumab Versus Other Biologics In Moderate To Severe Crohn’s Disease: A 1-Year Treatment Sequence Analysis (2016) (8)
Sa1761 - Efficacy and Safety of Dose Escalation to Tofacitinib 10 Mg Bid for Patients with Ulcerative Colitis Following Loss of Response on Tofacitinib 5 Mg Bid Maintenance Therapy: Results from Octave Open (2018) (8)
OP011 Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study (2014) (8)
Commentary: anaemia in inflammatory bowel disease – the most common and ignored extra intestinal manifestation (2014) (8)
IBD: Of mice and men—shedding new light on IL-13 activity in IBD (2011) (8)
Ustekinumab for treating ulcerative colitis: an expert opinion (2020) (8)
EMA response to ECCO position statement on biosimilars. (2014) (8)
Emerging therapies for the treatment of ulcerative colitis (2020) (8)
P653 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders (2018) (8)
Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach (2020) (8)
P574 The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trial (2018) (7)
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? (2021) (7)
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? (2016) (7)
S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study (2020) (7)
Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality? (2020) (7)
P198 MRE and colonoscopy findings in early Crohn's disease predict the course of the disease: a prospective observational cohort study (2013) (7)
Antibody to alpha4beta7 integrin for ulcerative colitis. (2005) (7)
Impact of therapies on bowel damage in Crohn’s disease (2020) (7)
DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial (2019) (7)
PF-00547659 for the treatment of Crohn’s disease and ulcerative colitis (2018) (7)
P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn’s disease: results of the ENTERPRISE study (2020) (7)
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. (2021) (7)
Characteristics Of Lymphoma In Patients With Inflammatory Bowel Disease: A Systematic Review. (2020) (7)
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) (2021) (7)
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. (2021) (7)
Adalimumab for the treatment of pediatric Crohn’s disease (2015) (7)
764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders (2016) (7)
Elevated homocysteine levels in patients with Raynaud's syndrome. (2000) (7)
Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience (2020) (7)
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis (2019) (7)
Bowel damage assessment in Crohn's disease by magnetic resonance imaging. (2012) (7)
Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders (2016) (7)
Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study (2021) (7)
Emerging therapeutic targets and strategies in Crohn’s disease (2016) (7)
Physicians’ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey (2018) (7)
Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn’s Disease: A Pilot Study (2021) (7)
P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. (2017) (7)
Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot. (2020) (7)
DOP078 Are IBD specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members (2014) (7)
Tolerance in intestinal inflammation and cancer. (2008) (7)
Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. (2021) (7)
Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity? (2020) (7)
The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment) (2022) (7)
Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? (2021) (7)
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)]. (2015) (6)
GPR120 prevents colorectal adenocarcinoma progression by sustaining the mucosal barrier integrity (2021) (6)
IBD in 2013: Enriching the therapeutic armamentarium for IBD (2014) (6)
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues (2021) (6)
775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study (2021) (6)
Viral infections in inflammatory bowel disease: Tips and tricks for correct management (2021) (6)
Thrombotic complications in inflammatory bowel disease: a multifactorial etiology (2001) (6)
P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease. (2017) (6)
Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models (2022) (6)
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial. (2022) (6)
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis (2021) (6)
Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. (2021) (6)
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis (2020) (6)
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis (2021) (6)
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: a systematic review and network meta-analysis. (2019) (6)
Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohnʼs Disease Treated with Vedolizumab: 1676 (2013) (6)
Editorial [ Inflammatory Bowel Disease and Inflammation-Associated Colon Cancer:Partners in Crime Guest Editor: Silvio Danese ] (2008) (6)
1005 – A Controlled Trial of Amiselimod, a Selective S1P Receptor Modulator in Crohn's Disease (2019) (6)
Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate (2014) (6)
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. (2022) (6)
Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm (2019) (6)
Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. (2009) (6)
Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis: 12-Week Results From the Phase 2 LATTICE-UC Study. (2022) (6)
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases (2022) (6)
Treatment of Perianal Fistulas in Crohn's Disease, Seton versus Anti-TNF versus Surgical Closure Following Anti-TNF (PISA): A Randomised Controlled Trial (2019) (6)
The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Goes Home. (2021) (6)
Does anti-TNF therapy cost so many COINs? (2014) (6)
Going Beyond Bacteria: Uncovering the Role of Archaeome and Mycobiome in Inflammatory Bowel Disease (2021) (6)
Defining difficult-to-treat inflammatory bowel disease: why and how. (2021) (6)
JAK selectivity: more precision less troubles (2020) (6)
Tofacitinib: janus bifrons in ulcerative colitis treatment. (2013) (6)
A prospective study comparison of narrow band imaging (NBI) versus chromoendoscopy with indigo carmine (IC) versus white light (WL) colonoscopy in the detection of adenomatous colonic lesions (2007) (6)
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. (2021) (6)
Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class? Authors’ reply (2018) (6)
Letter: immunogenicity of infliximab originator vs. CT‐P13 in IBD patients (2017) (6)
Regulatory T cells for immunotherapy of autoimmune diseases: from the bench to the bedside (2005) (5)
Statins and inflammatory bowel disease: Where do we stand? (2020) (5)
Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial (2020) (5)
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (2022) (5)
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD). (2004) (5)
949 EFFICACY AND SAFETY OF 2 VEDOLIZUMAB IV REGIMENS IN PATIENTS WITH PERIANAL FISTULIZING CROHN'S DISEASE: RESULTS OF THE ENTERPRISE STUDY (2020) (5)
Challenges and opportunities for IBD drug development: from early stage to regulatory approval (2020) (5)
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. (2022) (5)
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice (2020) (5)
Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis. (2020) (5)
Safety of vedolizumab in liver transplant recipients: A systematic review (2019) (5)
Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic (2020) (5)
Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment (2022) (5)
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. (2022) (5)
Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons. (2016) (5)
105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL (2021) (5)
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. (2022) (5)
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis (2021) (5)
OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study (2022) (5)
Golimumab: clinical update on its use for ulcerative colitis. (2015) (5)
Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial. (2022) (5)
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents (2021) (5)
Endpoints for perianal Crohn's disease trials: past, present, and future. (2021) (5)
Infliximab biosimilar CT-P13 for inflammatory bowel disease. (2018) (5)
DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II (2019) (5)
OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study (2021) (5)
Biosimilar therapies in inflammatory bowel disease: should we care about patient profile? (2016) (5)
OP009 Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial. (2017) (5)
New Drugs In The Ulcerative Colitis Pipeline: Prometheus Unbound. (2019) (5)
Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study. (2021) (5)
P303 Ulcerative colitis (UC) in the elderly – Moderate at onset but then a milder course? An IG-IBD study (2014) (5)
Heat shock protein 47 is a new candidate molecule as anti‐fibrotic treatment of Crohn’s disease: authors’ reply (2010) (5)
DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2 (2018) (5)
ECCO Position on harmonization of Crohn's disease mucosal histopathology. (2022) (5)
Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach (2019) (5)
Starving the inflamed gut: Angiogenesis blockade as a novel therapeutic approach to experimental colitis (2006) (5)
Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. (2020) (5)
Adalimumab for ulcerative colitis: a little is better than none? (2012) (5)
Tu1227 Effect of Oral Administration of Methylene Blue MMx® Tablets on Double-Stranded DNA Damage Assessed by γH2AX Analysis of Colon Biopsy Samples - A Single Center, Open Label, Safety, Phase II Study (2015) (4)
Lactobacillus paracasei CNCM I 1572: A Promising Candidate for Management of Colonic Diverticular Disease (2022) (4)
Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials. (2022) (4)
DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study (2019) (4)
OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial (2022) (4)
Endoscopic vacuum therapy for post-esophagectomy anastomotic dehiscence as rescue treatment: a single center case series (2022) (4)
Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time? (2019) (4)
OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM (2018) (4)
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. (2022) (4)
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease (2002) (4)
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations (2003) (4)
Inflammatory bowel diseases in italy: incidence trends and patients’ characteristics (2013) (4)
The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results. (2022) (4)
Regulatory T-cell therapy for Crohn's disease: in vivo veritas. (2012) (4)
Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. (2014) (4)
Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review (2021) (4)
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? (2015) (4)
Time to include patients with ulcerative proctitis in clinical trials. (2019) (4)
When can unfractionated heparin really be useful in the treatment of ulcerative colitis? (2001) (4)
Systematic review—pancreatic involvement in inflammatory bowel disease (2022) (4)
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience (2011) (4)
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? (2020) (4)
Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study (2021) (4)
Mesenchymal stromal cells in inflammatory bowel disease: conspirators within the ‘colitogenic niche’? (2012) (4)
Detection and management of early stage inflammatory bowel disease: an update for clinicians (2019) (4)
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures (2020) (4)
Inflammatory bowel disease and inflammation-associated colon cancer: partners in crime. (2008) (4)
DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis (2022) (4)
OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis (2022) (4)
856 Final Results of Phase II, Open Label, Study Investigating Polyp and Adenoma Detection Rate After Single Oral Dose of Methylene Blue MMx® Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy (2013) (4)
Is there a role for therapeutic sphingolipids in inflammatory bowel disease? (2019) (4)
Oral beclomethasone: a review of its use in inflammatory bowel disease. (2008) (4)
Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way? (2015) (4)
Iron deficiency: the hidden miscreant in inflammatory bowel disease. (2014) (4)
A snapshot of the ongoing clinical research on COVID-19 (2020) (4)
UEG Week 2016 Poster Presentations (2016) (4)
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. (2022) (4)
Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. (2020) (4)
OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis (2022) (4)
OP33 Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study (2021) (4)
367 – Vagus Nerve Stimulation Reduces Disease Activity and Modulates Serum and Autonomic Biomarkers in Biologicrefractory Crohn's Disease (2019) (4)
P545 Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition (2018) (4)
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial (2022) (3)
Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Maintenance Study (2019) (3)
S856 Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies (2021) (3)
Biologic Therapies in Ulcerative Colitis: Primi Inter Pares? (2018) (3)
Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY (2021) (3)
DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study (2020) (3)
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. (2021) (3)
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. (2017) (3)
Delphi initiative for early-onset colorectal cancer (DIRECt). International Management Guidelines. (2022) (3)
Evolving strategies and goals of treatment in ulcerative colitis. (2018) (3)
863 Tralokinumab (CAT-354), an Interleukin 13 Antibody, in Moderate to Severe Ulcerative Colitis: A Phase 2A Randomized Placebo-Controlled Study (2014) (3)
Post COVID-19 irritable bowel syndrome (2022) (3)
Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale? (2021) (3)
P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study. (2017) (3)
COVID-19 and digestive health (2020) (3)
Sphingosine‐1‐phosphate receptor 2 is a negative regulator of epithelial cell proliferation and intestinal tumorigenesis (2017) (3)
Evolving Treatment Algorithms in Crohn's Disease. (2016) (3)
Predicting future disease course in Crohn’s disease by colonoscopy or magnetic resonance: which is the crystal ball? (2015) (3)
Induction of Clinical and Endoscopic Remission of Mild to Moderately Active Ulcerative Colitis With Budesonide MMX (R) 9 mg: Analysis of Pooled Data from Two Phase 3 Studies (2011) (3)
Do JAK inhibitors have a realistic future in treating Crohn’s disease? (2021) (3)
Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases (2022) (3)
Switching from Infliximab Originator to CT-P13 is not Related to Increased Immunogenicity in IBD Patients: A Prospective Case-Control Study (2017) (3)
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis (2022) (3)
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. (2023) (3)
Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing. (2016) (3)
Obstructed defecation syndrome associated with paradoxical puborectalis contraction: osteopathic treatment versus anal biofeedback. Results of a pilot study (2021) (3)
Su1289 Development of Red Flags for Early Referral of Adults With Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative (2014) (3)
DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. (2017) (3)
Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes” (2018) (3)
S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study (2020) (3)
Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art (2022) (3)
Phase 1, 2 and 3 trials in inflammatory bowel diseases: a practical guide for the non-specialist. (2020) (3)
Therapeutic Response to Adalimumab in a Case of Steroid-Dependent Segmental Colitis Associated With Diverticulosis. (2021) (3)
IBD goes home: from telemedicine to self-administered advanced therapies (2021) (3)
P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies (2019) (3)
OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial (2022) (3)
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement (2021) (3)
Medical therapy versus surgery in moderate-to-severe ulcerative colitis. (2020) (3)
P016 Stimulation of lymphatic function via VEGFR-3 as a novel therapy for chronic experimental intestinal inflammation (2012) (3)
Su2087 Effect of Long-Term Budesonide MMx 6 mg use on Bone Mineral Density in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study (2012) (3)
Colorectal cancer screening: dying en route? (2010) (3)
P.02.12 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF DIVERTICULAR DISEASE OF THE COLON: A 1-YEAR ANALYSIS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY (2019) (3)
An unusual case of cardiac involvement in Crohn's Disease. (2020) (3)
T1687 Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease (2009) (3)
Efficacy of Ustekinumab for Ulcerative Colitis Through 2 Years: Results of the UNIFI Maintenance Study and Long-term Extension (2020) (3)
Anti TNF-alpha treatment for Crohn' disease: "ménage a trois". (2010) (3)
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies (2022) (3)
The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. (2012) (3)
Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference? (2019) (3)
S715 Clinical and Endoscopic Improvements With Risankizumab Induction and Maintenance Dosing versus Placebo Are Observed Irrespective of Number of Prior Failed Biologics (2022) (3)
P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II) (2019) (3)
Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology (2015) (3)
New mechanisms and targets for IBD Therapy: translational gastroenterology comes of age. (2013) (3)
Corrigendum to "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease" [Dig. Liver Dis. 48 (2016) 360-370]. (2016) (3)
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study (2022) (3)
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study (2022) (3)
P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019 (2020) (2)
Predictors for short bowel syndrome in Crohn's disease. (2020) (2)
S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study (2020) (2)
634 Transitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program (2019) (2)
Publisher Correction: Colonic diverticular disease (2020) (2)
835 – Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results from the Gemini Lts Study (2019) (2)
Endoscopy after surgery in inflammatory bowel disease: Crohn’s disease recurrence and pouch surveillance (2020) (2)
Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future (2022) (2)
388 Supplementation with the Probiotic VSL#3 in Patients with Mild-to-Moderate Active Ulcerative Colitis: A Double-Blind, Randomized, Placebo-Controlled Study (2009) (2)
Publisher Correction: Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis (2020) (2)
OP005 The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy. (2017) (2)
Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis (2021) (2)
Current Practice of Anemia Management in Patients With Inflammatory Bowel Disease Across Four European Countries (2011) (2)
Su446 PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY (2021) (2)
The Multiple Faces of Integrin–ECM Interactions in Inflammatory Bowel Disease (2021) (2)
A novel pathogenic role for microvasculature in inflammatory bowel disease. (2006) (2)
Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic. (2019) (2)
Treat to target in mild to moderate ulcerative colitis: evidence to support this strategy. (2020) (2)
325 - Factors Driving Treatment Escalation in Crohn's Disease in the Calm Trial (2018) (2)
Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease (2017) (2)
Commentary: antibodies reacting with the infliximab Fab portion – something new? (2013) (2)
P.12.9 MESALAZINE AND/OR LACTOBACILLUS CASEI IN MAINTAINING REMISSION OF SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (2013) (2)
P274 Factors driving treatment escalation in Crohn’s disease in the CALM trial (2018) (2)
Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION (2020) (2)
Timely Use of Biologics in Early Crohn’s Disease: The Return of “Hit Hard and Early”? (2019) (2)
Is selectivity the JAKpot winner for IBD treatment? (2022) (2)
A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohnʼs Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research: 598 (2017) (2)
Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease (2020) (2)
Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel (2016) (2)
OP21 Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study (2021) (2)
High oxygen free radicals generation in gastric mucosa infected by H. pylori cytotoxic strains (2000) (2)
W1245 Successful Induction of Clinical Response and Remission with Certolizumab Pegol in Crohn's Disease Patients Who Are Primary Non-Responders or Intolerant to Infliximab: A Real Life Multi-Center Experience of Compassionate Use (2008) (2)
Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm (2022) (2)
COVID-19 and gastrointestinal symptoms: the dust has not settled yet (2020) (2)
POSA350 Effect of Filgotinib on EQ-5D-5L and Work Productivity and Activity Impairment Among Patients with Ulcerative Colitis: Results from the Phase 2B/3 Selection Trial (2022) (2)
Improving quality of care in endoscopy of inflammatory bowel disease: can we do better? (2020) (2)
Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. (2019) (2)
Sa1240 Clinical Utility of the LéMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study (2015) (2)
813 - Apremilast for Active Ulcerative Colitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study (2018) (2)
689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial (2019) (2)
Drug development for ulcerative proctitis: current concepts (2021) (2)
Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. (2021) (2)
Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm (2018) (2)
Correction to: Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease (2020) (2)
Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. (2019) (2)
359 Stimulation of Lymphatic Function via VEGFR-3 as a Novel Therapy for Chronic Experimental Intestinal Inflammation (2012) (2)
128 SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS (2021) (2)
Long-Term Safety in the Open-Label Period of a Phase 2a Study of Brazikumab, an Antibody Against Interleukin-23 (2018) (2)
A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort (2017) (2)
Commentary: adjunct antibiotic combination therapy for ulcerative colitis – is it time to investigate Fusobacterium varium? (2014) (2)
Confounding and bias in observational studies in inflammatory bowel disease: a meta‐epidemiological study (2020) (2)
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. (2022) (2)
CX601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells (EASC), for Complex Perianal Fistulas in Crohn's Disease: Long-Term Results from a Phase III Randomized Controlled Trial (2017) (2)
Su1339 Ulcerative Colitis (UC) Diagnosed Over Age 65 Years -An IG-IBD Study (2014) (2)
S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE (2020) (2)
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance (2023) (2)
Does the mucosal microcirculation play a role in IBD? (2008) (2)
A New Extended Intestinal Release Formulation of Rifaximin, 400 mg Tablets, for the Treatment of Moderately Active Crohn's Disease (2011) (2)
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023) (2)
Dendritic cells, TGF-beta, and Integrin alphavbeta8 in inflammatory bowel disease: a tolerogenic "ménage à trois". (2008) (2)
93 Clinical and Endocopic Improvement Following Hemopoietic Stem Cell Transplantation vs Mobilisation Alone in Crohn's Disease (2013) (2)
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective (2019) (2)
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review (2022) (2)
Mo1332 MRE and Colonoscopy Findings in Early Crohn's Disease Predict the Course of the Disease: A Prospective Observational Cohort Study (2013) (2)
Su1742 Mesenchymal Stem Cells Ameliorate Experimental Colitis by Secretion of TNF-Alfa Stimulated Gene/Protein 6 and Not by Gut-Homing (2013) (2)
P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension (2020) (2)
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study (2011) (2)
Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study. (2020) (2)
Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. (2020) (2)
disease and ulcerative colitis functional capacity of mucosal T cells in Crohn's Divergent cell cycle kinetics underlie the distinct (2008) (2)
Is cytotoxic-associated gene A-positive Helicobacter pylori important? (2001) (2)
Predictors of Flares in Infliximab-treated Children With Inflammatory Bowel Disease (2019) (2)
Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? (2003) (2)
P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials (2022) (2)
Mo1041 MRE Findings at Crohn's Disease Diagnosis: Disease Activity, Bowel Damage and Predictive Value for Long-Term Outcomes (2012) (2)
Su1376 Retrospective Comparison of the Efficacy of Anti-TNF Agents in Isolation or Combined With Azathioprine in Prevention of Early Postoperative Endoscopic Recurrence in Crohn's Disease From the Multiper Database (2014) (2)
Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening (2005) (2)
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. (2017) (2)
DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis (2019) (2)
DOP87 Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study (2021) (2)
JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. (2020) (2)
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. (2017) (2)
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome (2013) (2)
Tu1739 – Efficacy and Safety of Ustekinumab Through Week 16 in Patients with Moderate to Severe Ulcerative Colitis Randomized to Ustekinumab: Results from the Unifi Induction Trial (2019) (2)
Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest Study (2019) (2)
CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems. (2005) (2)
Helicobacter pylori Infection and Migraine (2000) (2)
Treatment of Zenker's diverticulum : flexible endoscopy versus endoscopic stapling Comparison of efficacy and complications (2007) (2)
Non‐invasive monitoring and treat‐to‐target approach are cost‐effective in patients with mild–moderate ulcerative colitis (2022) (2)
P162 Induction of clinical and endoscopic remission with budesonide MMX in mild to moderately active ulcerative colitis: Pooled data from two phase 3 studies (2012) (2)
Helicobacter pylori infection affects oxygen free radicals generation and oxidative DNA damage in gastric mucosa (2001) (2)
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension (2020) (2)
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease. (2002) (2)
Faecal incontinence in inflammatory bowel disease: The Nancy experience. (2022) (2)
Gastric emptying study before gastric peroral endoscopic myotomy (G-POEM): can intragastric meal distribution be a predictor of success? (2022) (2)
Landscape of new drugs and targets in inflammatory bowel disease (2022) (2)
A multi-omic analysis reveals the esophageal dysbiosis as the predominant trait of eosinophilic esophagitis (2023) (2)
Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach! (2018) (2)
Gender, chronic infection and myocardial infarction (2000) (2)
Anti-TNF Therapy in Inflammatory Bowel Diseases (2010) (2)
P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis (2020) (2)
Editorial [Hot topic: Anti TNF-α Treatment for Crohns Disease: “Menage A Trois” (Guest Editor: Silvio Danese)] (2010) (2)
Author Correction: Crohn’s disease (2020) (2)
OP18 Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction treatment versus anti-TNF without surgery (PISA II) - A patient preference RCT (2021) (2)
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic (2020) (2)
Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Multinational, Phase 3 Clinical Trials: 569 (2016) (2)
Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies. (2009) (2)
Safety and tolerability of spesolimab in patients with ulcerative colitis (2022) (2)
Challenges and Opportunities in IBD Clinical Trial Design. (2021) (2)
P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial (2022) (2)
Surgical conduct in case of intraoperative detection of a Meckel's diverticulum in Crohn's disease. (2011) (2)
OTH-12 Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial (2019) (2)
Corticosteroid Sparing Effects of Ustekinumab Therapy for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension (2020) (2)
S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study (2021) (2)
Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease (2020) (2)
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension (2020) (2)
832 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies (2019) (2)
Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience (2022) (2)
OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies (2021) (2)
Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study (2022) (2)
P533 Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study (2018) (2)
OP35 Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn’s Disease - Week 48 analysis of the STARDUST trial (2021) (2)
Protecting patients with IBD during the COVID-19 pandemic (2020) (2)
Is it time to include older adults in inflammatory bowel disease trials? A call for action. (2022) (1)
Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2022) (1)
The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases (2021) (1)
P.06.16 INFLIXIMAB IN PATIENTS WITH ULCERATIVE COLITIS AND PRIMARY SCLEROSING CHOLANGITIS BEFORE AND AFTER HEPATIC TRANSPLANTATION (2012) (1)
Su1205 Long-Term Outcome of Treatment With Infliximab in Patients With Steroid-Dependent Ulcerative Colitis (2013) (1)
Sa1625 Colon Staining Efficacy of Methylene Blue MMx® 25 mg Modified Release Tablets, Administered As Single Ascending Oral Doses of 150 and 200 mg in Outpatients Colonoscopy (2012) (1)
DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease (2020) (1)
P511 Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database (2014) (1)
Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD) (2022) (1)
274 Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: A Randomised, Double-Blind, Placebo-Controlled Study (2013) (1)
Correction to: Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis (2020) (1)
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. (2016) (1)
Infliximab and azathioprine for Crohn's disease: a super-sonic combination? (2010) (1)
P827 The clinical phenotype of collagenous colitis is associated with T-cell-related genetic variants (2020) (1)
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. (2022) (1)
Improvement in Patient Quality of Life during Treatment with Infliximab, Azathioprine, or Combination Infliximab+Azathioprine for Moderate-to-severe Ulcerative Colitis: 1806 (2013) (1)
Endoscopic surveillance in IBD: The VIRTUE is in high definition. (2021) (1)
Editorial. Medical challanges in inflammatory bowel disease: quo vadis in disease complexity? (2014) (1)
PTH-077 De-escalating therapy in patients with crohn’s disease receiving adalimumab: subgroup analysis of the calm study (2019) (1)
W1213 Lymphoneogenesis: A New Component in Inflammatory Bowel Disease Pathogenesis (2008) (1)
DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2021) (1)
P067 IBD98E promotes mucosal wound healing through epithelial cell proliferation in DSS-induced colitis (2014) (1)
[Therapy of carcinoma in situ]. (1985) (1)
P230 Ultrasonography-based and Magnetic Resonance-based Lémann Index: two sides of the same coin (2022) (1)
Endoscopic vacuum therapy in the treatment of postesophagectomy leaks: Is intracavitary the way? (2022) (1)
S0779 Effect of Ustekinumab Maintenance Therapy on Stool Frequency and Rectal Bleeding Through 2 Years in the UNIFI Phase 3 Study in Ulcerative Colitis (2020) (1)
269 Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn's Disease: Partial Benefit by Infliximab - a Pilot Study (2012) (1)
Editorial: CCR7 is required for leukocyte egression in an experimental model of Crohn's disease‐like ileitis (2015) (1)
P054 In experimental model of colitis the therapeutic efficacy of mesenchymal stem cells is not gut-homing dependent but is mediated at distance by secretion of TNF-alfa stimulated gene/protein 6 (2013) (1)
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply (2020) (1)
Corrigendum to ‘Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor’ (2020) (1)
Comparison between intravenous iron gluconate alone and intravenous iron gluconate plus levofolinic acid for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease (2006) (1)
Sa1887 – General Health Status in Patients with Moderate to Severe Ulcerative Colitis Receiving Ustekinumab: Results from the Phase 3 Unifi Induction and Maintenance Studies (2019) (1)
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis (2023) (1)
945 HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY (2020) (1)
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. (2018) (1)
PTH-091 Effects of vedolizumab on HRQoL and work productivity in Crohn’s disease: results from versify (2019) (1)
Author response to: Covid-19-related pancreatic injury (2020) (1)
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo (2023) (1)
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance (2022) (1)
Cardio-intestinal inflammatory syndromes: Evidence ready for prime time. (2023) (1)
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling (2018) (1)
Filgotinib for moderately to severely active ulcerative colitis (2022) (1)
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient (2021) (1)
1127 Infliximab in Steroid-Dependent Ulcerative Colitis: Efficacy and Predictors of Clinical and Endoscopic Remission (2012) (1)
Early combined immunosuppression in Crohn's disease (2008) (1)
Sa1408 Predictive Value of the “DICA” Endoscopic Classification on the Outcome of Diverticular Disease of the Colon: An International Study (2016) (1)
Su1871 VALIDATION OF THE RED FLAGS INDEX FOR EARLY DIAGNOSIS OF CROHN'S DISEASE: A PROSPECTIVE GENERAL PRACTITIONER STUDY (2020) (1)
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. (2023) (1)
Introduction (2014) (1)
Correction to: Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis (2020) (1)
Su1803 - Correlation of Endoscopic and Clinical Endpoints During Induction Therapy in Patients with Moderate to Severe Crohn's Disease: Analysis from Celest Study (2018) (1)
Tu1886 DOSE ADJUSTMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI MAINTENANCE STUDY LONG-TERM EXTENSION (2020) (1)
DOP098 The risk of postoperative complications following preoperative immunosuppressive therapy in patients undergoing ileocolonic resection for Crohn's disease (2014) (1)
The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis (2014) (1)
Author Correction: Colonic diverticular disease (2020) (1)
137 Conditional Deletion of Prep1 in the Intestinal Epithelium Alters Epithelial Homeostasis, Intestinal Development, and Controls Colitis Susceptibility (2014) (1)
Psychological Functioning of Patients With Inflammatory Bowel Disease. (2019) (1)
Evaluation of subclinical exocrine pancreatic involvement in primitive Sjogren's syndrome (pSS) by mixed triglyceride breath test and fecal chymotrypsin and its relation with Schirmer's test (2000) (1)
Mo1360 A New Tool for Pre-Colonoscopy Dying of the Colonic Mucosa With Oral Multi Matrix Release Technology (MMX®)-Released Methylene Blue: A Preliminary Study of Absorption, Bioavailability and Toxicity (2011) (1)
S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study (2021) (1)
P547 Biological agents for moderately-to-severely active ulcerative colitis in adults: a network meta-analysis of randomized controlled trials (2014) (1)
Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic (2020) (1)
19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study (2016) (1)
Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii (2019) (1)
Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab (2020) (1)
DOP008 The absence of the Triggering Receptor Expressed on Myeloid Cells type-2 (TREM-2) induces a transmissible and protective intestinal microbiota for colitis and colitis associated cancer (2014) (1)
S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies (2021) (1)
P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib (2019) (1)
Leukoapheresis in Crohn's disease: the final curtain? (2012) (1)
SUPPLEMENTATION WITH THE PROBIOTIC VSL#3 IN PATIENTS WITH MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY (2009) (1)
The oft-overlooked cardiovascular complications of inflammatory bowel disease (2023) (1)
DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies (2022) (1)
P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study (2021) (1)
Editorial. Imaging inflammatory bowel disease: looking beyond the mucosa. (2012) (1)
DOP036 Lémann Index assessment over time in Crohn's disease patients treated with anti TNFs: a pilot observational cohort study (2014) (1)
Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease (2021) (1)
The new frontier: Certifying quality standards in the inflammatory bowel disease care. (2021) (1)
450 Value of Preoperative Magnetic Resonance Enterography to Predict Surgical Findings and to Guide Decisions in Crohn's Disease: A Prospective Study (2013) (1)
OC-014 Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisatiion alone in Crohn’S Disease (2013) (1)
Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis (2022) (1)
New magnetic resonance imaging sequences for fibrosis assessment in Crohn’s disease: a pilot study (2022) (1)
Fr537 EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY (2021) (1)
Is Mesalamine Effective for the Induction of Remission in Crohn's Disease? (2017) (1)
Helicobacter pylori and ischemic heart disease: current evidences. (1999) (1)
AODWE-008 Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn`s disease with perianal fistula (2017) (1)
article : infliximab for Crohn ’ s disease treatment – shifting therapeutic strategies after 10 years of clinical experience (2011) (1)
OP33 BUB1: a new player in the development of Crohn’s disease (CD)-associated fibrosis (2019) (1)
Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era (2022) (1)
P605 Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA. (2017) (1)
DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis (2021) (1)
S853 Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies (2021) (1)
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel (2022) (1)
OP37 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study (2021) (1)
DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study) (2022) (1)
P056 - Autologous Stem Cell Transplantation For Crohn's disease (ASTIC) trial: early report of toxicity and efficacy (2009) (1)
Treatment of Acute Malignant Colorectal Obstruction with WallflexTM Colonic Stents: A Prospective Study (2007) (1)
879 A Prospective, Single Center Study of Endoscopic Submucosal Dissection of Rectal LST Lesions Larger Than 3 cm by Using an Innovative Concept of Injecting and Cutting: The Water-Jet Hybrid-Knife (ESD-H) (2011) (1)
Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (2022) (1)
Inflammatory Bowel Disease in Migrant Populations: Should we look Even Further Back? (2021) (1)
Is It Crohn’s Disease? (2020) (1)
Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question (2022) (1)
OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO (2023) (1)
Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease (2022) (1)
Tu1955 Fecal Calprotectin Reductions in Patients With Mucosal Healing During Vedolizumab Induction Therapy in GEMINI 1 (2016) (1)
149 Intestinal Microbiota Defined by the Absence of the Triggering Receptor Expressed on Myeloid Cells Type-2 (TREM-2) Is Transmissible and Protects From Colitis Associated Cancer (2014) (1)
Assessment of prothrombotic risk in patients with Behçet's disease should include homocysteine plasma levels. (2001) (1)
P.01.9 INCIDENCE AND TIME TRENDS OF INFLAMMATORY BOWEL DISEASES IN LOMBARDY FROM 2003 TO 2009 (2013) (1)
Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring? (2021) (1)
Drug Development for Inflammatory Bowel Disease: Interaction Among Academia, Industry and Regulatory Authorities. (2016) (1)
S743 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results From the UNIFI Long-Term Extension (2022) (1)
S692 Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study (2021) (1)
Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows (2022) (1)
Italian Consensus Statement for Promoting Psycho-Social Wellbeing and Engagement in the Care of Inflammatory Bowel Disease Patients (2021) (1)
Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials (2020) (1)
Lynphoneogenesis : a new component in inflammatory bowel disease pathogenesis (2007) (1)
PC.01.2 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF THE DIVERTICULAR DISEASE OF THE COLON: AN INTERNATIONAL STUDY (2016) (1)
P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study (2022) (1)
PTH-094 Indirect treatment comparison of ustekinumab versus other biologics in moderate to severe crohn’s disease: a 1-year treatment sequence analysis (2017) (1)
Reply. (2020) (1)
Identification of Serum and Tissue Micro-RNA Expression Profiles in Different Stages of the Inflammatory Bowel Disease (2011) (1)
W1271 Anti-TNF Therapy in Elderly People in IBD: An Italian Multicentre Survey (2010) (1)
P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension (1)
OC3.11.4 SUCCESSFUL INDUCTION OF CLINICAL RESPONSE AND REMISSION WITH CERTOLIZUMAB PEGOL CROHN'S DISEASE PATIENTS: A MULTI-CENTER EXPERIENCE OF COMPASSIONATE USE (2008) (1)
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn′s Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition (2022) (1)
S730 Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator- and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From True North (2022) (1)
P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study (2019) (1)
High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2. (2022) (1)
Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients. (2022) (1)
DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis (2022) (1)
Tu1855 EFFICACY AND SAFETY OF ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH UC FOLLOWING LOSS OF RESPONSE ON 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN-LABEL, LONGTERM EXTENSION STUDY (2020) (1)
Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer (2020) (1)
DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial (2020) (1)
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis (2022) (1)
Response (2020) (1)
Tu1879 EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH USTEKINUMAB IN MODERATE-SEVERE ULCERATIVE COLITIS PATIENTS WITH DELAYED RESPONSE TO USTEKINUMAB INDUCTION: RESULTS FROM THE UNIFI 2-YEAR LONG-TERM EXTENSION (2020) (1)
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. (2019) (1)
Placebo rates in randomized controlled trials of proctitis therapy: A systematic review and meta-analysis. (2022) (1)
1027 SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY (2020) (1)
S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies (2021) (1)
New and emerging therapies for inflammatory bowel disease. (2012) (1)
Available methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs. (2022) (1)
P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective observational study (2023) (1)
Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSION (2020) (1)
277: A NEW SIMPLIFIED HISTOLOGY ARTIFICIAL INTELLIGENCE SYSTEM FOR ACCURATE ASSESSMENT OF REMISSION IN ULCERATIVE COLITIS (2022) (1)
772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II (2019) (1)
S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study (2021) (1)
A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY (2022) (1)
Sa1240 LéMann Index Assessment Overtime in Crohn's Disease Patients Treated With Anti TNFs: A Pilot Observational Cohort Study (2014) (1)
Sa1739 Comparative Proteome Profiling of Intestinal Epithelial Cells in Mice and IBD Patients (2014) (1)
Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions (2022) (1)
Endoscopic Vacuum Therapy (EVT) versus Self-Expandable Metal Stent (SEMS) for Anastomotic Leaks after Upper Gastrointestinal Surgery: Systematic Review and Meta-Analysis (2023) (1)
Rapid Detection of Anti-Infliximab Antibodies in Inflammatory Bowel Disease Patients Treated with the Reference Biologic or the Biosimilar CT-P13: Performance Comparison with Elisa (2017) (1)
Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic. (2023) (1)
950 THE VISIBLE 2 PHASE 3 STUDY OF EFFICACY AND SAFETY OF VEDOLIZUMAB SC FOR MODERATE-TO-SEVERE CROHN'S DISEASE (2020) (1)
215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE (2019) (1)
Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis (P7-3.007) (2023) (0)
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. (2018) (0)
Gender, chronic infection and myocardial infarction (multiple letters) (2000) (0)
Vedolizumab for the Treatment of Chronic Pouchitis. (2023) (0)
P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies (2023) (0)
M1410: Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial (2010) (0)
Su1565: EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY AGE: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION AND SELECTIONLTE STUDIES (2022) (0)
P385 Risk-benefit assessment of IBD drugs: a physicians and patients survey (2023) (0)
P362 Retrospective comparison of the efficacy of anti-TNF agents in isolation or combined with azathioprine in prevention of early postoperative endoscopic recurrence in Crohn's disease from the MULTIPER database (2014) (0)
Modification of the course of inflammatory bowel disease ( IBD ) during pregnancy and after delivery (2013) (0)
PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study (2016) (0)
High prevalence of celiac disease in Migraine (2001) (0)
Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1: 1638 (2014) (0)
OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC (2023) (0)
Resolved Hypereosinophilic Syndrome and Immune Thrombocytopenic Purpura in Ulcerative Colitis Patients Post Colectomy: A Case Series and Literature Review (2022) (0)
Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab (2020) (0)
S0664 Disease Control and Changes in Individual Treatment Outcomes From Week 14 to Week 52 With Vedolizumab or Adalimumab in Ulcerative Colitis: A VARSITY Trial Post Hoc Analysis (2020) (0)
Anti saccharomices cerevisiae antibodies (ASCA) assay in an Italian population of inflammatory bowel disease (2000) (0)
P.1.91: A PROSPECTIVE, SINGLE CENTER STUDY OF ENDOSCOPIC SUBMUCOSAL DISSECTION OF RECTAL LST LESIONS > 3 CM BY USING AN INNOVATIVE CONCEPT OF INJECTING AND CUTTING: THE WATER-JET HYBRID-KNIFE (ESD-H) (2011) (0)
Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis (2019) (0)
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes (2018) (0)
[Conservative therapy of breast carcinoma]. (1985) (0)
P.1.20: A NEW TOOL FOR PRE-COLONOSCOPY DYING OF THE COLONIC MUCOSA WITH ORAL MULTI MATRIX RELEASE TECHNOLOGY (MMX®)-RELEASED METHYLENE BLUE: A PRELIMINARY STUDY (2011) (0)
P021 The urokinase plasminogen activator receptor (uPAR) regulates intestinal macrophage phagocytosis and polarization in experimental colitis (2013) (0)
Tu1749 – Pharmacokinetics and Exposure-Response Relationships of Intravenously Administered Ustekinumab During Induction Treatment in Patients with Ulcerative Colitis: Results from the Unifi Induction Study (2019) (0)
P050 Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study. (2017) (0)
Front & Back Matter (2022) (0)
Su1897 TRANSMURAL HEALING WITH VEDOLIZUMAB IN PATIENTS WITH ACTIVE CROHN'S DISEASE (2020) (0)
Unique Function of Protein C in Controlling Epithelial Tight Junction Expression and in Regulating Mucosal Healing in Experimental Colitis (2011) (0)
OC1.08.1 THE ATYPICAL CHEMOKINE RECEPTOR D6 CONTROLS INTESTINAL INFLAMMATION AND INFLAMMATION-ASSOCIATED COLON CANCER (2008) (0)
OC.06.1: Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in two Multinational, Phase 3 Clinical Trials (2017) (0)
Immune and non-immune components orchestrate the pathogenesis of 1 inflammatory bowel disease 2 3 4 (2011) (0)
EXTRAGASTRO-DUODENAL MANIFESTATIONS OF HELICOBACTER PYLORI INFECTION (1999) (0)
685 Risk Factor Analysis for Therapy Related Adverse Events and Infections in Elder Patients With Inflammatory Bowel Disease; An Analysis From the iG-IBD Aged Study (2015) (0)
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases (2022) (0)
Clinical Pathologic Challenge Saxophone Penis: Challenge. (2023) (0)
Induction of Colitis in Mice and Overexpression of VEGF-A and sVEGFR-1 Using Adenovirus Colitis (2009) (0)
Tu1863 TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE TO ANTI-TL1A THERAPY IN ULCERATIVE COLITIS: THE PHASE 2A TUSCANY STUDY (2020) (0)
What's Hot in the Red Journal This Month (2010) (0)
Su1522: ULTRASONOGRAPHY-BASED AND MAGNETIC RESONANCE-BASED LÉMANN INDEX: TWO SIDES OF THE SAME COIN. (2022) (0)
Sa1869 The PA System Controls Inflammatory Response During Experimental Colitis (2012) (0)
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents (2017) (0)
OC3.03.2 LYMPHONEOGENESIS: A NEW COMPONENT IN INFLAMMATORY BOWEL DISEASE PATHOGENESIS (2008) (0)
EARLY AND LATE OUTCOME OF ENDOSCOPIC AMPULLARY RESECTION FOR EARLY NEOPLASIA OF THE PAPILLA OF VATER (2009) (0)
Acknowledgment of 2008 Reviewers (2009) (0)
Mo1097 Adalimumab Improves Treatment Satisfaction With Medication and Work Productivity Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA (2016) (0)
Critical role of map kinases in governing lymphocyte adhesion to and migration across microvasculature in inflammatory bowel disease (IBD) (2006) (0)
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach (2018) (0)
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement (2021) (0)
Front & Back Matter (2021) (0)
P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis (2023) (0)
Tu1440: LONG-TERM CUMULATIVE SAFETY OF USTEKINUMAB IN BIONAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS (2022) (0)
S696 Efficacy of Ustekinumab for Ulcerative Colitis in Patients Through 3 Years: UNIFI Long-term Extension (2021) (0)
P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis (2020) (0)
Tu1872 IDENTIFICATION OF BIOMARKERS AND MECHANISTIC INSIGHT FOR UPADACITINIB IN ULCERATIVE COLITIS: ANALYSIS OF SERUM INFLAMMATORY MEDIATORS IN THE PHASE 2B U-ACHIEVE STUDY (2020) (0)
Author Correction: The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework (2021) (0)
OC.01.6: SELF-EXPANDABLE BIODEGRADABLE STENT IN THE MANAGEMENT OF REFRACTORY BENIGN COLORECTAL STRICTURES: PRELIMINARY RESULTS FROM A PILOT STUDY (2011) (0)
Front & Back Matter (2020) (0)
T.01.9 TRANSORAL INCISIONLESS FUNDOPLICATION FOR GASTROESOPHAGEAL REFLUX DISEASE INDUCES ESOPHAGEAL MUCOSAL HEALING UP TO TWO YEARS AFTER THE INTERVENTION AS DOCUMENTED BY THE MEAN NOCTURNAL BASELINE IMPEDANCE (2022) (0)
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (cid:2) (Cortiment (cid:2) MMX (cid:2) ) for active, mild-to-moderate ulcerative colitis (2019) (0)
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies (2019) (0)
Functional hyporesponsiveness of lamina propria T cells is reflected by a muted tyrosine phosphorylation of the T cell receptor signaling cascade (2003) (0)
DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study (2023) (0)
Ulcerative Colitis: Today, Tomorrow, and the Future (2020) (0)
P549 Dose optimization is effective in patients with ulcerative colitis losing response to infliximab: a collaborative multicentre retrospective study (2013) (0)
Migraine: First symptom of cryptic coeliac disease? (2001) (0)
Fellows training and job opportunities in Italy: Preliminary results of the aggei survey (2006) (0)
P.05.1 QUALITY OF CARE IN INFLAMMATORY BOWEL DISEASE IN ITALY ACCORDING TO IBD CHARACTERISTICS: INITIAL RESULTS FROM SOLUTION TRIAL (AN ONGOING PROSPECTIVE IG-IBD STUDY) (2012) (0)
966: EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2022) (0)
Comparing Interleukin-12 / 23 and Anti-Tumour Necrosis Factor ‘ Real-World ’ Registry Data in Psoriasis and Psoriatic Arthritis Doctor (2017) (0)
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment (2015) (0)
18 P Expression of metalloproteinases 1, 3 and 9 in gastric mucosa is not dependent by helicobacter pylori infection (2002) (0)
584: VEDOLIZUMAB INTRAVENOUS IS EFFECTIVE ACROSS MULTIPLE TREATMENT TARGETS IN CHRONIC POUCHITIS: RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EARNEST TRIAL (2022) (0)
Anti-saccharomyces cerevisiae mannan antibodies: Are they useful in clinical practice? (2001) (0)
Su1540 Self-Expandable Biodegradable Stent in the Management of Refractory Benign Colorectal Strictures: Preliminary Results From a Pilot Study (2011) (0)
Clinical pharmacists and patients with inflammatory bowel diseases: are we ready for the multidisciplinary approach? (2021) (0)
Intestinal TCR Signaling Threshold Redox Equilibrium in Mucosal T Cells Tunes (2005) (0)
P129 Intestinal ultrasound at week 12 predicts long-term endoscopic response to biologics in ulcerative colitis (2023) (0)
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. (2023) (0)
P051 Inhibition of lymphangiogenesis via VEGFR-3 as a novel therapy for IBD-related colorectal cancer (2013) (0)
The thrombomodulin-activated protein C-endothelial protein C receptor pathway: A novel anti-inflammatory system in inflammatory bowel disease (2006) (0)
Editorial: treat‐to‐target in ulcerative colitis clinical management—a small price to pay? Authors' reply (2023) (0)
P348 Disease trajectories in ulcerative colitis: Early identification of patients with endoscopic remission at Week 52 (2023) (0)
401 The Atypical Chemokine Receptor D6 Controls Intestinal Inflammation and Inflammation-Associated Colon Cancer (2008) (0)
Guts and Love (2016) (0)
Sa1881 – Effects of Intravenous Vedolizumab on Health-Related Quality of Life and Work Productivity in Patients with Crohn’s Disease: Results from the Phase 3B Versify Trial (2019) (0)
P494 Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. (2017) (0)
644 Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program (2019) (0)
Stimulation of the omega-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease (2016) (0)
W1609 The Anticoagulant Protein C System Is Expressed and Functionally Active in Mucosal Dendritic and Epithelial Cells and Is Down-Regulated in IBD Patients (2009) (0)
Early Biological Therapy in Operated Crohn’s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience (2022) (0)
DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial (2022) (0)
OC-072 Differences in therapy approaches and outcomes in paediatric and adult onset crohn’s disease with perianal fistula: comparison of 2 ecco collaborative multicentre fistula cohorts (2017) (0)
Front & Back Matter (2021) (0)
PWE-033 Presentation and surgical interventions for crohn’s diseasewith perianal fistula in the biologics era: results from a multicentre study (2017) (0)
M1768 Junctional Adhesion Molecule – A is a New Key Regulator in Colitis Associated Colon Cancer (2010) (0)
Physician-patient communication is key to improve IBD management during COVID-19 pandemic (2021) (0)
P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials (2023) (0)
P506 Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho study. (2017) (0)
P593 A patient's perspective on anaemia in inflammatory bowel disease (2013) (0)
14: MALIGNANCIES IN PATIENTS TREATED WITH USTEKINUMAB: LONG-TERM POOLED SAFETY ANALYSIS IN CROHN'S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS (2022) (0)
Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology (2015) (0)
Mo1911 – Serum Bile Acids Profiling in IBD Patients Treated with Antitnf (2019) (0)
596 Silencing of Prolyl Hydroxylase 1 in Intestinal Microvascular Endothelial Cells Prevents Inflammation-Induced Endothelial Dysfunction and Dampens Murine Colitis (2014) (0)
Artificial intelligence in endoscopic assessment of ulcerative colitis: virtual painting with PICaSSO (2023) (0)
Centrally-Determined Standardization of Flow Cytometry Methods Reduces Inter-Laboratory Variation in a Prospective Multicenter Study (2017) (0)
P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study (2019) (0)
888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY (2022) (0)
Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases. (2023) (0)
P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis (2022) (0)
P.01.17 DIRECT HEALTHCARE COSTS OF INFLAMMATORY BOWEL DISEASES IN LOMBARDY (2013) (0)
approach to experimental colitis Angiogenesis blockade as a new therapeutic (2008) (0)
Multicentre Cohort Study to Evaluate the Need for Re-Intervention following Multimodal Treatment in Crohn`s Disease with Perianal Fistula (2017) (0)
852 Cx601, Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells (eASC), for Complex Perianal Fistulas in Crohn's Disease: Results From a Phase III Randomized Controlled Trial (2016) (0)
Long-term data supports the established efficacy and safety of ustekinumab in UC (2023) (0)
Mo1518: EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN’S DISEASE: RESULTS FROM THE STARDUST TRIAL (2022) (0)
GPR120 prevents colorectal adenocarcinoma progression by sustaining the mucosal barrier integrity (2022) (0)
Tu1889 UPADACITINIB WAS NOT ASSOCIATED WITH ANAEMIA IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE U-ACHIEVE STUDY (2020) (0)
Evolution of IL-23 Blockade in Inflammatory Bowel Disease (2022) (0)
Narrow-band imaging endoscopy as a novel tool to assess in vivo mucosal angiogenesis in inflammatory bowel disease (2007) (0)
4 - The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6 (2009) (0)
Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply (2022) (0)
P681 Serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease (2013) (0)
P574 Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials (2023) (0)
Sphingosine-1-Phosphate Receptor 3 Orchestrates Epithelial-Mesenchymal Transition Promoting Intestinal Fibrosis in CD Patients (2017) (0)
129 SAFETY OF USTEKINUMAB IN IBD: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC (2021) (0)
Unraveling TNFalpha‐stimulated gene 6 (TSG‐6) function in switching stemness and biological properties of mesenchymal stem cells (2017) (0)
P004 Stimulation of CYP450-mediated ω-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease. (2017) (0)
P602 Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials (2023) (0)
P.71 ANTI-TNF THERAPY IN ELDERLY PEOPLE IN IBD: AN ITALIAN MULTICENTRE SURVEY (2010) (0)
5 P Do homocysteine levels and polymorphisms of homocysteine metabolism-related enzymes determine extent of bone loss in inflammatory bowel disease? (2002) (0)
PC.01.2 DISEASE CLEARANCE AS A NEW THERAPEUTIC TARGET IN PATIENTS WITH ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE COHORT STUDY (2021) (0)
Stimulation of CYP450-Mediated Î©-3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease (2017) (0)
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience (2016) (0)
Reply (2021) (0)
Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease. (2022) (0)
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. (2023) (0)
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report (2010) (0)
Relationships Between Intestinal Ultrasound Parameters and Histopathologic Findings in a Prospective Cohort of Patients With Crohn's Disease Undergoing Surgery. (2023) (0)
P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey. (2017) (0)
P747 Adherence to ECCO guidelines for cancer surveillance is associated to the detection of early cancer: A retrospective, single-centre, cohort study (2020) (0)
Postoperative Complications Are Associated With an Early and Increased Rate of Disease Recurrence After Surgery for Crohn’s Disease (2022) (0)
Su1238 Contrast-Enhancement at Magnetic Resonance Enterography Does Not Differentiate Between Fibrosis and Inflammation in Crohn's Disease: A Prospective Cohort Study (2015) (0)
Could small molecules be used in combination with biologics for inflammatory bowel disease? (2022) (0)
DOP016 Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammation (2018) (0)
Patients’ perceptions of surgery for inflammatory bowel disease (2021) (0)
936 Inhibition of Lymphangiogenesis As a Novel Therapy for IBD-Related Colorectal Cancer (2013) (0)
Endoscopic internal drainage versus endoscopic vacuum therapy for upper gastrointestinal leaks: what's the real deal? (2022) (0)
S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction (2022) (0)
S20 The lymphatic system undergoes lymphangiogenesis and governs an inflammation-dependent mechanism for leukocyte transmigration in IBD patients (2010) (0)
Letter: pancreatic involvement in inflammatory bowel disease—authors' reply (2022) (0)
Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease (2022) (0)
OP40 Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial (2021) (0)
P211 Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicentre fistula cohorts. (2017) (0)
A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high rate of restorative minimally invasive surgery. (2021) (0)
P.01.1 LONG-TERM OUTCOME IN STEROID-DEPENDENT ULCERATIVE COLITIS TREATED WITH INFLIXIMAB (2013) (0)
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial. (2023) (0)
P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study (2020) (0)
Tu1449: EFFICACY AND SAFETY OF ADVANCED INDUCTION AND MAINTENANCE THERAPIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INDIRECT TREATMENT COMPARISON USING BAYESIAN NETWORK META-ANALYSIS (2022) (0)
Su1513: IMPACT OF MODERATE-TO-SEVERE ENDOSCOPIC DISEASE CRITERIA ON ENDOSCOPIC RESPONSE, ENDOSCOPIC REMISSION, AND DEEP REMISSION IN PATIENTS RECEIVING USTEKINUMAB OR ADALIMUMAB IN THE SEAVUE STUDY (2022) (0)
New Therapies for IBD: From the Bench to the Bedside (2015) (0)
Inflammatory bowel disease meets fertility: A physician and patient survey. (2023) (0)
Sa461 THE INFLAMMATORY BOWEL DISEASE – DISTRIBUTION, CHRONICITY, ACTIVITY (IBD-DCA) SCORE IS A NEW PROMISING INDEX FOR HISTOLOGIC ACTIVITY ASSESSMENT IN ULCERATIVE COLITIS AND CROHNS DISEASE (2021) (0)
Editorial: long‐term safety and efficacy of certolizumab pegol for Crohn's disease (2014) (0)
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from SELECTION. (2023) (0)
Tu1447: IZENCITINIB INDUCTION TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (2022) (0)
1006 Combination of Laparoscopy and Enhanced Recovery Program Improves Outcomes After Ileocecal Resection for Crohn's Disease (2012) (0)
OC1.10.5 IT KNIFE-2 FOR THE TREATMENT OF FLAT COLORECTAL LESIONS LARGER THAN 3 CM: PRELIMINARY RESULTS FROM THE FIRST APPLICATION OF THIS DEVICE IN COLONIC LESIONS (2008) (0)
DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative Colitis (2022) (0)
P174 Critical Role of Map Kinases in Governing Lymphocyte Adhesion to and Migration Across Microvasculature in Inflammatory Bowel Disease (2007) (0)
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LST LARGER THAN 30 MM (2009) (0)
Safety profile of infliximab in inflammatory bowel disease: Single-center experience in 102 patients and 672 infusions (2006) (0)
P194 Methylene Blue orally administered tablets (MB MMX®) is effective in detecting intraepithelial dysplasia in patients with long standing ulcerative colitis (2013) (0)
P330 Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn’s disease (2023) (0)
Helicobacter pylori and ischemic heart (2005) (0)
715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program (2019) (0)
OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results (2023) (0)
Crucial role of vegf in IBD : at the cross-road between immune-driven angiogenesis and inflammation (2007) (0)
PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis (2021) (0)
Comparative Accuracy of us Versus MRI and Colonoscopy in Assessing Disease Activity and Complications and Influencing the Decision-Making Process in Crohn's Disease (2017) (0)
ROLE OF JUNCTIONAL ADHESION MOLECULE-A IN MAINTAINING MUCOSAL HOMEOSTASIS IN INFLAMMATORY BOWEL DISEASE A (2008) (0)
Correction to: Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management (2020) (0)
S826 Baseline and Early Predictors of Response to Risankizumab Induction and Maintenance Treatment in Patients With Moderate to Severe Crohn's Disease (2022) (0)
P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis (2019) (0)
Meet Our Regional Editor (2020) (0)
Tu1875 IMPACT OF DISEASE DURATION ON TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS (2020) (0)
Presentation and Surgical Interventions for Crohn's Disease with Perianal Fistula in the Biologics Era: Results from a Multicentre Study (2017) (0)
Meet the Regional Editor (2021) (0)
Continued efficacy of long-term ozanimod as UC treatment (2023) (0)
Digestive Diseases. Introduction. (2014) (0)
P331 Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies (2022) (0)
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults. (2023) (0)
High homocystein levels in inflammatory bowel disease (2000) (0)
partici-Folate in gastrointestinal health and disease (2012) (0)
P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies (2023) (0)
Tu1237 - Epidemiology of Diverticular Disease of the Colon: A Preliminary Analysis from the International “Dica” Prospective Study (2018) (0)
P472 Infliximab therapy for inflammatory bowel disease in patients post liver transplatation (2013) (0)
P240 Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. (2017) (0)
Gastrointestinal system, COVID-19 and potential mechanisms associated with coagulopathy. (2022) (0)
Predictive value of bowel ultrasound in Crohn's disease: a 12-month prospective study Reply to: Dr Xiaofei's Letter. (2021) (0)
Fertility and assisted reproductive technologies outcomes of women with non-surgically managed inflammatory bowel diseases: a systematic review. (2022) (0)
T.08.2 SYSTEMATIC REVIEW AND META-ANALYSIS: ENDOSCOPIC VACUUM THERAPY (EVT) VERSUS SELF-EXPANDABLE METAL STENT (SEMS) FOR ANASTOMOTIC LEAKS AFTER UPPER GASTROINTESTINAL SURGERY (2023) (0)
A preclinical platform for the radiolabelling and in vivo monitoring of nanoparticles against Crohn’s Disease using live dynamic SPECT imaging (2022) (0)
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2022) (0)
Inflammation and malnutrition in inflammatory bowel disease. (2023) (0)
S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease (2022) (0)
DOP36 Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: A multicenter, prospective cohort study (2021) (0)
Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge (2022) (0)
Front & Back Matter (2022) (0)
P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA. (2017) (0)
DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study (2021) (0)
How Relevant is the Homing of Mesenchymal Stem Cells Into the Inflamed Gut to Their Therapeutic Efficacy in Experimental Colitis (2011) (0)
DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease (2020) (0)
Carcinomas in inflammatory bowel disease: a narrative review on diagnostic imaging techniques. (2021) (0)
InflammationAdaptive Immunity, Coagulation, and Endothelial Cells: Directing Innate and Immune Regulation by Microvascular (2007) (0)
Tract afety and efficacy of sodium hyaluronate ( IBD 98 E ) in the induction f clinical and endoscopic remission in subjects with distal lcerative colitis (2014) (0)
P.02.2 INFLIXIMAB THERAPY FOR INFLAMMATORY BOWEL DISEASE IN PATIENTS POST LIVER TRANSPLANTATION (2013) (0)
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease (2023) (0)
P244 Validation of the Red Flags index for early diagnosis of Crohn’s disease: A prospective general practitioner study (2020) (0)
P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study (2020) (0)
Letter to the editorThrombotic complications in inflammatory bowel disease: a multifactorial etiology (2001) (0)
Tu1452: EARLY MODIFICATION OF INFLAMMATORY BURDEN THROUGH TREATMENT WITH VEDOLIZUMAB OR ADALIMUMAB IS PREDICTIVE OF LONG-TERM TREATMENT SUCCESS IN PATIENTS WITH ULCERATIVE COLITIS FROM THE VARSITY STUDY (2022) (0)
Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases. (2019) (0)
Use of heparin in inflammatory bowel disease. A meta-analysis (2000) (0)
Vedolizumab Results in Durable Clinical Remission in Crohn’s Disease: 1614 (2014) (0)
Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap? (2019) (0)
Real World Mucosal Healing With Vedolizumab in Crohnʼs Disease: A Systematic Review and Meta-Analysis (2018) (0)
Infliximab inSteroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinicaland Endoscopic Remission. (2013) (0)
P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial (2019) (0)
DOP018 Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA. (2017) (0)
DOP082 Identified areas of need to enhance evidence-based inflammatory bowel disease management and patient care (2014) (0)
Reply (2020) (0)
A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL (2022) (0)
Brief review Biosimilars - terms of use (2015) (0)
The potential role of vascular endothelial growth factor-A in IBD pathogenesis (2009) (0)
847u The Bacterial Sensor Triggering Receptor Expressed on Myeloid Cells 2 (TREM-2) is a Crucial Pathogenic Mediator in Inflammatory Bowel Disease (IBD) (2010) (0)
afety of treatments for inflammatory bowel disease : Clinical practice uidelines of the Italian Group for the Study of Inflammatory Bowel isease ( IG-IBD ) (2017) (0)
697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis (2019) (0)
OC.04.4 ULTRASOUND REMISSION AFTER BIOLOGIC INDUCTION PREDICTS LONG-TERM ENDOSCOPIC REMISSION IN CROHN'S DISEASE (2023) (0)
OC3.05.5 INVOLVEMENT OF THE CD40/CD40 LIGAND PATHWAY IN COELIAC DISEASE (2008) (0)
P734 A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn’s disease prognosis - a prospective study (2023) (0)
P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations (2023) (0)
S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study (2021) (0)
P015 The VEGFC/VEGFR3 pathway controls colitis associated cancer formation and progression through lymphangiogenesis and lymphatic endothelial VE-cadherin (2014) (0)
P309 Ferritin or transferrin saturation vs. soluble transferrin receptor for iron deficiency diagnosis in inflammatory bowel disease (2020) (0)
P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis (2020) (0)
OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME (2023) (0)
Su1377 Does the Location of an IBD Centre Impact the Rates of Early Postoperative Endoscopic Recurrence After Ileocecal Resection in Crohn's Disease? Results From the Multiper Database (2014) (0)
P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study (2021) (0)
OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial (2023) (0)
Su1531: SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS (2022) (0)
Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. (2022) (0)
Dynamic Management of Crohn’s Disease: Reaching a New Dimension in Patient Care (2020) (0)
P351 Bowel ultrasound is accurate in assessing disease activity in ulcerative colitis (2018) (0)
Illness Perception in IBD Patients: A Prospective Study (2017) (0)
Sa1836 Stimulation of the ω-3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease (2016) (0)
Sa1792 PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE OUTCOMES WITH VEDOLIZUMAB VERSUS ADALIMUMAB TREATMENT OF ULCERATIVE COLITIS: RESULTS OF THE VARSITY TRIAL (2020) (0)
Wallflex colonic stents in the treatment of acute malignant colorectal obstruction (2007) (0)
Activated platelets contribute to inflammatory bowel disease (IBD) pathogenesis through release of rantes which mediates T-cell adhesion to intestinal microvascular endothelial cells (HIMEC) (2003) (0)
757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY (2019) (0)
716 Early Clinical Response and Remission With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY (2019) (0)
Tu1719 – Clinical Remission by Legacy Versus Fda Definitions: Definition Justification and Results from Unifi Study (2019) (0)
Front & Back Matter (2022) (0)
Interleukin-23 Inhibition as a Strategy to Treat Immune-Mediated Inflammatory Diseases : A Focus on Psoriasis (2018) (0)
P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study (2023) (0)
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? (2017) (0)
S854 Upadacitinib Is Effective at Inducing Clinical Remission and Response in Ulcerative Colitis Patients Regardless of Baseline Corticosteroid Use: Results From Two Phase 3 Studies (2021) (0)
DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study (2020) (0)
Challenging full-thickness resection of post endoscopic mucosectomy residual scar in right colon, accessed via a balloon-dilated stoma (2022) (0)
Long-Term Outcomes of Crohn's Perianal Fistulas Treatment: Short-Term Anti-Tnf Therapy with Surgical Closure Versus Anti-TNF Therapy (PISA-II) - A Patient Preference RCT (2022) (0)
Publisher Correction: Crohn’s disease (2020) (0)
Crohn's disease: Bacterial clearance in Crohn's disease pathogenesis (2010) (0)
Ongoing results of SINEO (Spectroscopic Investigation of Near Earth Objects) survey (2005) (0)
P584 Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis (2023) (0)
S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study (2022) (0)
Editorial: Personalized Medicine in Inflammatory Bowel Diseases: Myth or Reality? (2018) (0)
Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease. (2022) (0)
Sa1075 Safety of Sodium Picosulphate-Based Bowel Preparation: A Meta-Analysis. (2016) (0)
Novel approach to endoscopic submucosal dissection using an additional working channel: a case report. (2022) (0)
S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12 (2022) (0)
Supernovae 2003L, 2003M, and 2003O (2003) (0)
OC.10.1 SUPERIOR PREDICTIVE VALUE OF INTESTINAL ULTRASOUND OVER ENDOSCOPIC SEVERITY FOR COLECTOMY RISK IN PATIENTS WITH ULCERATIVE COLITIS (2023) (0)
OP19 Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trials (2022) (0)
Placebo response rates in randomized controlled trials for perianal Crohn's disease: A systematic review and meta-analysis. (2022) (0)
OC.16.5 PROPOFOL TARGET-CONTROLLED INFUSION (TCI) BY GASTROENTEROLOGISTS FOR ENDOSCOPIC PROCEDURES: A RETROSPECTIVE ANALYSIS OF PATIENT SAFETY AND SATISFACTION (2022) (0)
Mo1090 The Costs of Care for Patients With Ulcerative Colitis: Effect of Adalimumab on Health Care Resources Utilisation in Clinical Practice From INSPIRADA (2016) (0)
[Follow-up in a patient treated for carcinoma of the breast]. (1985) (0)
Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada (2017) (0)
Combining Mechanisms of Action to Treat Patients With Inflammatory Bowel Disease. (2023) (0)
New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. (2020) (0)
P020 Silencing of prolyl hydroxylase 1 in intestinal microvascular endothelial cells prevents inflammation-induced endothelial dysfunction and dampens murine colitis (2014) (0)
P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies (2019) (0)
Sa1879 EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION FOLLOWING TREATMENT INTERRUPTION: POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA (2020) (0)
Tu1459: CORRELATION OF HISTOLOGICAL ASSESSMENT OF MUCOSAL HEALING WITH LONG-TERM CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM PHASE 3 U-ACHIEVE MAINTENANCE TRIAL (2022) (0)
M1229 A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience (2010) (0)
Mo1519: CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL (2022) (0)
DOP080 Increasing colectomy rates over time in ulcerative colitis and the impact of thiopurines: A nationwide cohort study (2014) (0)
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply (2020) (0)
OC3.03.4 UNIQUE ROLE OF JUNCTIONAL ADHESION MOLECULE-A IN MAINTAINING MUCOSAL HOMEOSTASIS IN INFLAMMATORY BOWEL DISEASE (2008) (0)
SYSTEMATIC REVIEWS AND META-ANALYSES (0)
P.13.2 COLON STAINING EFFICACY OF METHYLENE BLUE MMX® 25 MG MODIFIED RELEASE TABLETS, ADMINISTERED AS SINGLE ASCENDING ORAL DOSES OF 150 AND 200 MG IN OUTPATIENTS COLONOSCOPY (2012) (0)
Anti-Inflammatory Mechanism of Infliximab Microcirculation: A Novel CD40/CD40L Pathway in the Mucosal Blockade Down-Regulates the α TNF- (2013) (0)
Novel Mediator of T Cell Tolerance Granulocyte Colony-Stimulating Factor: A (2013) (0)
Mo1665 The VEGFC/VEGFR3 Pathway Controls Colitis Associated Cancer Formation and Progression Through Lymphangiogenesis and Lymphatic Endothelial VECadherin (2014) (0)
Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS (2021) (0)
7 PS CD40 ligand-positive activated platelets contribute directly to inflammatory bowel disease (IBD) pathogenesis through production of IL-8 and rantes (2002) (0)
OC.03.3 MOLECULAR AND MICROBIOTA PROFILING IN EOSINOPHILIC ESOPHAGITIS: A TRANSCRIPTOME AND META-TRANSCRIPTOME META-ANALYSIS (2023) (0)
AF.154 NON-INVASIVE ASSESSMENT OF POSTOPERATIVE DISEASE RECURRENCE IN CROHN’S DISEASE: A MULTICENTER, PROSPECTIVE COHORT STUDY (2021) (0)
Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY (2022) (0)
P265 - Induction and modulation of T cell regulatory function by intestinal fibroblasts: inhibitory effect of intestinal inflammation (2009) (0)
P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension (2023) (0)
REPLY TO GASTRO-D-19-02389. (2020) (0)
P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD (2023) (0)
Identifying, understanding and managing fecal urgency in inflammatory bowel diseases. (2023) (0)
ag) Chemokines in inflammatory bowel disease. (2005) (0)
P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials (2023) (0)
Risk-Benefit of IBD Drugs: A Physicians and Patients Survey (2023) (0)
Su1516: A COMPARATIVE ANALYSIS BETWEEN INFLIXIMAB AND VEDOLIZUMAB ON PATIENTS WITH CROHN'S DISEASES AND ULCERATIVE COLITIS WHO DISCONTINUED DURING MAINTENANCE TREATMENT DUE TO LACK OF EFFICACY: META-ANALYSIS USING RANDOMIZED CONTROLLED TRIALS (2022) (0)
P473 Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn’s disease: Week 48 analyses from the phase 2 GALAXI 1 study (2023) (0)
Reply (2021) (0)
DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD) (2023) (0)
P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial (2021) (0)
Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks. (2022) (0)
Sa575 FILGOTINIB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: SF-36 RESULTS FROM THE PHASE 2B/3 SELECTION STUDY (2021) (0)
OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results (2023) (0)
P.05.17 EFFICACY OF DIVER-100 IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): PRELIMINARY RESULTS FROM A PROSPECTIVE OBSERVATIONAL COHORT (2018) (0)
Front & Back Matter (2021) (0)
Crohn ' s Disease Anti-Inflammatory Mechanism of Infliximab Microcirculation : A Novel CD 40 / CD 40 L Pathway in the Mucosal Blockade Down-Regulates the α TNF (2006) (0)
P.12.23 DIAGNOSTIC ACCURACY OF MMX-MB PANCHROMOCOLONOSCOPY IN PIT PATTERN ASSESSMENT AND CHARACTERIZATION OF NEOPLASTIC AND NON-NEOPLASTIC COLONIC LESIONS (PRELIMINARY DATA) (2013) (0)
Author Index / Subject Index (2013) (0)
BALANCED PROPOFOL SEDATION ADMINISTERED BY NON ANESTHESIOLOGISTS IN UPPER GASTROINTESTINAL ENDOSONOGRAPHY. A SINGLE CENTER PROSPECTIVE EXPERIENCE (2009) (0)
Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY (2020) (0)
P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study (2022) (0)
Detailed guidelines regarding the content are included in the Instructions to Authors. (2015) (0)
Su1220 Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study (2013) (0)
Homocysteine levels are not related to the extent of bone loss in patients with inflammatory bowel disease (2006) (0)
Can we change the natural course of inflammatory bowel disease? (2023) (0)
OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension (2023) (0)
684 INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL DEVELOPMENT PROGRAM: AN UPDATE AS OF MAY 2019 (2020) (0)
Corrigendum: Perception of Reproductive Health in Women with Inflammatory Bowel Disease. (2019) (0)
Editorial: vedolizumab in inflammatory bowel diseases—less is more? Authors’ reply (2021) (0)
Tu1865 VEDOLIZUMAB TREATMENT PERSISTENCE AND SAFETY IN AN EXTENDED ACCESS PROGRAM (XAP) (2020) (0)
Editorial: evidence is growing for protective effects of 5‐aminosalicylates against colitis‐associated cancer—authors’ reply (2017) (0)
P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy (2023) (0)
Amelioration of murine colitis by feeding colifagina, a novel preparation of 8 lysed bacteria (2007) (0)
P277 Comparative accuracy of US versus MRI and colonoscopy in assessing disease activity and complications and influencing the decision-making process in Crohn's disease. (2017) (0)
Cover Picture: Eur. J. Immunol. 5/09 (2009) (0)
Su1540: MILAN ULTRASOUND CRITERIA ARE ACCURATE IN ASSESSING ENDOSCOPIC REMISSION AND TREATMENT RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS. (2022) (0)
Sa1807 USTEKINUMAB MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI LONGTERM EXTENSION (2020) (0)
P366 Enhanced recovery program applied to laparoscopic ileocecal resection for Crohn's disease (2012) (0)
842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI (2019) (0)
Sa1753 - Tofacitinib Achieves Symptomatic Improvement within 3 Days in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior Tumour Necrosis Factor Inhibitor Treatment Status: Results from Octave Induction 1 & 2 (2018) (0)
List of reviewers for 2010 (2011) (0)
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients (2023) (0)
P28 Effect of endoscopic disease criteria on endoscopic outcomes in the SEAVUE study (2022) (0)
Accepted Manuscript Anemia in IBD : the opening of Pandora ’ s box ? (2015) (0)
Su1803 THE CLINICAL PHENOTYPE OF COLLAGENOUS COLITIS IS ASSOCIATED WITH T CELL RELATED GENETIC VARIANTS (2020) (0)
IBD 2014: Thinking Out of the Box: Falk Symposium 192, Paris, May 2014 (2014) (0)
Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II) (2018) (0)
P029 Serum bile acids profiling in IBD patients treated with anti-TNFs (2019) (0)
High prevalence of Helicobacter pylori CAG-A positive cytotoxic strains in ischemic stroke (2000) (0)
P534 Illness perception in IBD patients: a prospective study. (2017) (0)
Sa1852 Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study (2012) (0)
OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo (2023) (0)
MFSD2A promotes epoxygenation of docosahexaenoic acid in gut endothelium to generate pro-resolving lipid mediators and dampen intestinal inflammation (2017) (0)
Ozanimod for moderate-to-severe Ulcerative Colitis (UC): efficacy, safety, and histology results from the induction and maintenance periods of the Phase 3 TRUE NORTH Study (2021) (0)
INVOLVEMENT OF THE CD40/CD40 LIGAND PATHWAY IN COELIAC DISEASE (2008) (0)
More on Covid-19 in Immune-Mediated Inflammatory Diseases. (2020) (0)
Caso pro diagnosi (Tumore trichilemmale maligno) (2000) (0)
Subject Index Vol. 32, Suppl. 1, 2014 (2014) (0)
Front & Back Matter (2020) (0)
Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2: 609 (2017) (0)
Su1267 Methylene Blue Orally Administered Tablets (Mb MMx®) Is Effective in Detecting Intraepithelial Dysplasia in Patients With Long Standing Ulcerative Colitis: Results From an Open Label Trial (2013) (0)
Author Correction: Head-to-head trials in inflammatory bowel disease: past, present and future (2021) (0)
Contents Vol. 38, 2022 (2022) (0)
P081 Rapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II (2019) (0)
OC.09.6 PREDICTIVE VALUE OF MILAN ULTRASOUND CRITERIA IN ULCERATIVE COLITIS: A PROSPECTIVE OBSERVATIONAL COHORT STUDY (2021) (0)
P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trial (2021) (0)
Sa1195 The Efficacy of Azathioprine and Tumour Necrosis Factor Antagonists in Preventing Crohn's Disease Recurrence After Ileal Resection: A Tertiary Center Real-Life Experience (2015) (0)
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs (2022) (0)
P015 The PA system controls inflammatory response during experimental colitis (2012) (0)
A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL (2022) (0)
5 Prep1: a new player in the development of IBD-associated fibrosis (2013) (0)
Pouch Dysfunction in Colitis (2018) (0)
AJG-21-1347 147..157 (0)
Mo1479: PERIANAL FISTULA CLOSURE IN PATIENTS RECEIVING USTEKINUMAB: RESULTS FROM THE SEAVUE AND STARDUST TRIALS (2022) (0)
Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply (2018) (0)
OC.03.4 EFFECT OF TUMOR NECROSIS FACTOR-ALPHA BLOCKADE ON MUCOSAL ADDRESSIN CELL-ADHESION MOLECULE-1 (MADCAM-1) EXPRESSION IN CROHN'S DISEASE (2012) (0)
S722 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Active Ulcerative Colitis Receiving 16 Weeks Extended Induction Treatment Followed by 52 Weeks Maintenance Treatment in U-ACHIEVE/U-ACCOMPLISH Trials (2022) (0)
P270 Infliximab in patients with ulcerative colitis and primary sclerosing cholangitis before and after liver transplatation (2012) (0)
Sa073 USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL (2021) (0)
Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease (2018) (0)
DIAGNOSTIC VALUE OF DISTAL COLONIC ADENOMAS FOR DETECTION OF ADVANCED PROXIMAL NEOPLASMS IN AN AVERAGE RISK POPULATION. A PROSPECTIVE STUDY (2009) (0)
article : the pathophysiology and medical management of diverticulosis and diverticular disease of the colon (2015) (0)
DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial (2020) (0)
Sa1793 EFFICACY AND SAFETY OF IRON CARBOXYMALTOSE ON CHRONIC FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RANDOMIZED CONTROLLED TRIAL (2020) (0)
Thrombomodulin-activated Protein C-Endothelial Protein C Receptor Pathway: A Novel Anti-inflammatory System in IBD (2006) (0)
P661 Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn’s disease: data from the ADVANCE and MOTIVATE studies (2023) (0)
Position paper on prevention of surgical site infections in obstetric and gynecological surgery (2020) (0)
A challenging endoscopic approach to an unexpected case of extraluminal recurrence after rectal surgery (2023) (0)
Contents, Vol. 35, 2019 (2019) (0)
O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials (2022) (0)
Mo1273 Prep1: A New Player in the Development of IBD-Associated Fibrosis (2013) (0)
Letter to the Editor Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index. (2021) (0)
The Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders (2023) (0)
S1028 Symptoms and Laboratory Values as Proxies for Endoscopic and Histologic Clinical Endpoints in Ulcerative Colitis: A Mediation Analysis Based on Upadacitinib Phase 3 Induction Trials (2022) (0)
EFFECTIVENESS OF ENDOSCOPIC SUBMUCOSAL DISSECTION (2009) (0)
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis (2023) (0)
Front & Back Matter (2022) (0)
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis (2023) (0)
Clinical and endoscopic improvement following haemopoietic stem cell transplantation on behalf of the Autoimmune Diseases Working Party of the EBMT (2013) (0)
chemokine decoy receptor D 6 and inflammation-associated colon cancer through the The lymphatic system controls intestinal inflammation (0)
Su1835 Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience (2016) (0)
Early intestinal ultrasound predicts long-term endoscopic response to biologics in ulcerative colitis. (2023) (0)
Su1086 Identified Areas of Need to Enhance Evidence-Based Inflammatory Bowel Disease Management and Patient Care (2014) (0)
Letter to the Editor. (2022) (0)
Su463 VEDOLIZUMAB RATES OF MUCOSAL HEALING IN CROHN'S DISEASE: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF REAL-WORLD DATA (2021) (0)
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases (2013) (0)
P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis (2022) (0)
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (2020) (0)
P435 Management of iron deficiency in inflammatory bowel disease: results from a RAND/UCLA appropriateness study (2013) (0)
P122 External validation of the Picasso Histological Remission Index (PHRI) to assess endoscopic and histological remission and predict long-term outcome in Ulcerative Colitis: A multicentre prospective study (2023) (0)
Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors (2023) (0)
Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials. (2021) (0)
LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study (2022) (0)
P173 CRITICAL ROLE OF EPITHELIAL JUNCTIONAL ADHESION MOLECULE-A IN EXPERIMENTAL COLITIS (2007) (0)
Advanced Techniques for Diagnosis of IBD (2013) (0)
Gastroparesis: The Complex Interplay with Microbiota and the Role of Exogenous Infections in the Pathogenesis of the Disease (2023) (0)
OP04 Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients (2023) (0)
Anti-Adhesion Molecules and Crohn’s Disease: Natalizumab in the Spotlight (2011) (0)
Tu1866 EFFICACY AND SAFETY OF AN ADDITIONAL 8 WEEKS OF TOFACITINIB INDUCTION THERAPY: UPDATED RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB 8-WEEK INDUCTION NON-RESPONDERS (2020) (0)
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis. (2022) (0)
P722 Upadacitinib was not associated with anaemia in patients with moderately to severely active ulcerative colitis: Results from the U-ACHIEVE study (2020) (0)
Mo1698 IBD98E Improves Experimental Colitis and Promotes Wound Healing Through Epithelial Cell Proliferation (2014) (0)
P237 Superior predictive value of intestinal ultrasound over endoscopic severity for colectomy risk in patients with ulcerative colitis (2023) (0)
Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn’s disease? Sounds good to US. Authors' reply (2022) (0)
DOP002 Conditional deletion of Prep1 in the intestinal epithelium alters epithelial homeostasis, intestinal development, and controls colitis susceptibility (2014) (0)
Sa1888 – Ustekinumab Therapy Induced Clinically Meaningful Improvement and Remission As Measured by the Inflammatory Bowel Disease Questionnaire in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Induction and Maintenance Studies (2019) (0)
Narrow-Band Imaging Endoscopy As a Novel Tool to Assess In Vivo Mucosal Angiogenesis in Inflammatory Bowel Disease: A Preliminary Report (2007) (0)
Fr536 EARLY ONSET OF RESPONSE WITH INTRAVENOUS VEDOLIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED IN THE VISIBLE 2 STUDY (2021) (0)
Amplification Pathway for Immune Response Granular RANTES Release: A Novel CD40-Dependent Platelet Activation and Cutting Edge: T Cells Trigger (2004) (0)
Front & Back Matter (2021) (0)
P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials (2023) (0)
Alterations o f Mesenchyma l and Endothelia l Cells in Inflammator y Bowel Diseases (2006) (0)
Sa1780 - Bowel Ultrasound is Accurate in Assessing Disease Activity in Ulcerative Colitis (2018) (0)
S740 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study (2022) (0)
P117 Low-Intensity Pulsed Ultrasound as a new approach of gut disruptive liquid biopsy to boost the release of mucosal extracellular vesicles in Ulcerative Colitis (2023) (0)
Su1887 POINT-OF-CARE BOWEL ULTRASOUND FOR DETECTING ILEO-COLONIC INFLAMMATION IN CROHN'S DISEASE. (2020) (0)
Contents Vol. 6, 2021 (2021) (0)
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials (2023) (0)
Tu1713 – Efficacy and Safety of 2 Or 3 Vedolizumab Intravenous Infusions As Induction Therapy for Ulcerative Colitis and Crohn's Disease: Results from Visible 1 and 2 (2019) (0)
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study (2020) (0)
The VEGF-VEGF receptor pathway is up-regulated and mediates mucosal angiogenesis in human and experimental inflammatory bowel disease (2006) (0)
P.05.7 EPIDEMIOLOGY OF DIVERTICULAR DISEASE OF THE COLON: A PRELIMINARY ANALYSIS FROM THE INTERNATIONAL “DICA” PROSPECTIVE STUDY (2018) (0)
Mini‐invasive technique for peroral endoscopic myotomy in adult patient: “Slim peroral endoscopic myotomy” procedure (2022) (0)
Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis. (2023) (0)
OC.11.1 GASTRIC PERORAL ENDOSCOPIC MYOTOMY (G-POEM) FOR REFRACTORY GASTROPARESIS: 12-MONTH FOLLOW-UP RESULTS FROM AN ITALIAN TERTIARY HOSPITAL (2022) (0)
S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years (2021) (0)
Clinical Pathologic Challenge Saxophone Penis: Challenge. (2023) (0)
MODULATION OF T CELL REGULATORY FUNCTION BY INTESTINAL FIBROBLASTS: WHERE INFLAMMATION INHIBITS IMMUNE-REGULATION (2009) (0)
S1637 Unexpected Role of Coagulative Protein in Controlling Epithelial Barrier Integrity and Intestinal Inflammation (2009) (0)
P45 Combining clinical, biological, and health-related quality of life remission with endoscopic improvements: data from SELECTION (2022) (0)
Adalimumab biosimilar in inflammatory bowel disease. (2021) (0)
P619 Inflammatory bowel disease meets fertility: a physicians and patients survey (2023) (0)
P163 Crucial Role of The Protein C Pathway In Governing Microvascular Inflammation in Inflammatory Bowel Disease (2007) (0)
P469 Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis (2023) (0)
P765 Role of C-reactive protein kinetics after surgery for Crohn’s disease (2018) (0)
Artificial Intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. (2023) (0)
P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis (2023) (0)
P191 SELECTIVE INDUCTION OF CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) LAMINA PROPRIA MONONUCLEAR CELLS (LPMC) APOPTOSIS BY PROBIOTICS: INVOLVEMENT OF BACTERIAL SPHINGOMYELINASE (SMAse) (2007) (0)
DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP) (2020) (0)
817 Identification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohn’s Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST Study (2019) (0)
V.2.2 FIBRIN GLUE ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION OF AN EARLY SQUAMOUS NEOPLASIA OF THE ESOPHAGUS IN A PATIENT WITH F2 GRADE ESOPHAGEAL VARICES (2010) (0)
Tu1864 ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST INTERIM ANALYSIS (2020) (0)
Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada (2017) (0)
P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment (2023) (0)
Front & Back Matter (2022) (0)
Tu1800 – A Prospective Multicenter Observational Cohort Study Assessing the Effectiveness of Budesonide Mmx® for Mildto-Moderate Ulcerative Colitis (2019) (0)
Helicobacter pylori infection and multiple myeloma: Is there a link? (2000) (0)
P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2 (2019) (0)
P273 Point-of-care bowel ultrasound for detecting ileocolonic inflammation in Crohn’s disease (2020) (0)
OC.10.2 ADHERENCE OF GENERAL PRACTITIONERS TO ITALIAN RECOMMENDATIONS ON THE PRESCRIPTION OF PROTON PUMP INHIBITORS (2020) (0)
JAK inhibitors in crohn’s disease: ready to go? (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Silvio Danese?

Silvio Danese is affiliated with the following schools:

University of Milan
Vita-Salute San Raffaele University
Humanitas University